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Epithelial ovarian cancer (EOC) is the most prevalent form of ovarian cancer, 
with its’ asymptomatic nature making early detection difficult, resulting in 
late-stage diagnosis with poor prognostic outcome. EOC cells metastasize via 
the formation of spheroids that dissociate from the primary tumour to 
resuspend in the patient ascites, eventually reattaching along the peritoneal 
cavity. Previously, in vitro culture of ovarian cancer spheroids showed up-
regulated expression of Frizzled-7 (FZD7), a WNT receptor. Furthermore, 
FZD7 expression was enriched in EOC cell lines displaying a stem-like 
molecular expression profile, suggesting a role of FZD7 in the maintenance of 
spheroids in ovarian cancer. In this study, stable knockdown of FZD7 in 
spheroid-forming EOC cells disrupted spheroid formation, with cells 
undergoing anoikis when cultured in suspension, which was further 
substantiated with increased Annexin V population and the up-regulation of 
apoptotic markers. The findings of this study suggest WNT signalling to be 
involved in protecting EOC cells from undergoing anoikis, thereby promoting 
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CHAPTER 1.1 
Epithelial Ovarian Cancer (EOC) 
   Ovarian cancer is the seventh most prevalent cancer among women in the 
world,1 and the fifth most in industrialized/ resource-rich nations, including the 
United States2 and Singapore3. It is the most deadly among gynecological 
malignancies, partly due to the asymptomatic nature of the disease, making 
early detection difficult. As such, majority of patients (61%) when presented 
are diagnosed at the later stages of disease progression, with only 15% of 
patients being diagnosed at stage I (localized).2 Prognosis of patients with stage 
I (localized) ovarian cancer is good, with a 5-year survival rate of 92%, 
drastically falling to just 27% for patients diagnosed at stage IV (distant).2 
   Majority of ovarian cancer display an epithelial morphology (90%) and are 
generally termed epithelial ovarian cancer (EOC). From a histopathological 
perspective, EOC is classified into four major histological subtypes: serous, 
endometrioid, mucinous and clear cell.4 Ovarian serous carcinoma is the most 
prevalent within EOC, which can be further classified into either high-grade or 
low-grade (reviewed in Gilks and Prat, 2009).5 The prevalence of the major 
histological subtypes of EOC is as follow: high-grade serous (70%), 
endometrioid (10%), clear cell (10%), low-grade serous (<5%) and mucinous 
(3%). Furthermore, depending on the presence of stromal invasion, each 
histological subtype may be subdivided into benign, borderline (low malignant 
potential, LMP) or malignant.6 
   Tumours of serous, endometrioid and mucinous histological subtypes 
resemble the epithelium of the Müllerian duct derivatives during embryonic 
development, namely: fallopian tubes, endometrium and endocervix 
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respectively. Clear cell tumours morphologically resemble cells of the 
gastrointestinal tract and renal cells, suggesting a non-ovarian origin.7 The 
heterogeneity within EOC suggests different histological subtypes representing 
different cell of origins.7 However, conventional treatment strategies for 
ovarian cancer does not take this heterogeneity into account, with patients of 
all histological subtypes receiving a standard mix of platinum-taxane-based 
chemotherapeutic reagents as the first-line of treatment with variable 
outcome.8-11 This underlines a critical lapse in our understanding of ovarian 
cancer, thus improved therapeutic outcome would require better appreciation of 
the molecular aspects of the disease.  
   In attempts to better classify ovarian cancer towards better prediction of 
clinical response, various groups have analysed the molecular expression 
profiles of the histological subtypes of ovarian cancer, with an emphasis on the 
most prevalent and aggressive high-grade serous subtype which accounts for 
two-thirds of all ovarian cancer mortalities.12 Mutually exclusive BRAF and 
KRAS mutations were found in accumulatively 61% of low-grade serous 
ovarian carcinomas (LGSOC), whereas high-grade serous ovarian carcinomas 
(HGSOC) carry wild-type BRAF and KRAS.13 However, ~50% of HGSOC 
carry TP53 mutations 14 while 14-26% carry germline mutations for BRCA1/2 
tumour suppressor genes.15 Somatic mutations in sporadic HGSOC are rare, 
though epigenetic silencing via promoter hypermethylation of BRCA1 has been 
reported in ~33% of cases.16 Taken together, these results suggest that HGSOC 
and LGSOC are mediated by different molecular pathways and may therefore 
be two distinct subtypes altogether of different origins.13 Interestingly, 
classification of 47 ovarian cancer cell lines from the Broad-Novartis Cancer 
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Cell Line Encyclopedia (CCLE) based on HGSOC & LGSOC molecular 
subtype expression profiles identified several less commonly used lines 
(COV318, KURAMOCHI, OVKATE, OVSAHO, SNU119) that show greater 
genetic similarities to HGSOC than the more commonly used serous lines, such 
as A2780, HEY A8, OAW42 and SKOV-3.17 
   Another study by the same group proposed a dualistic classification model 
(type I and type II) based on accumulative clinicopathological and molecular 
studies reported previously, with type I ovarian carcinoma encompassing the 
low-grade serous, low-grade endometrioid, mucinous and clear cell 
carcinomas. Type I ovarian tumours are generally less aggressive, indolent in 
nature and usually presented at low stages (stages I and II). They resemble 
benign, borderline and low-grade tumours, suggesting type I tumours to follow 
a conventional neoplastic-to-tumourigenic progression model.18 Molecular 
expression profile of type I ovarian tumours include mutations in specific 
subset of genes for various histopathologies, including:  BRAF, KRAS and 
ERRB2 (low-grade serous), PTEN, CTNNB1 and PIK3CA (low-grade 
endometrioid), KRAS (mucinous) and activating PIK3CA mutations (clear cell). 
Type II ovarian tumours encompass high-grade serous, high-grade 
endometrioid and undifferentiated carcinomas. They are generally 
characterized to be more aggressive and associated with late stage of disease 
(stages III and IV) and poor prognosis. Molecular expression profiles of type II 
ovarian tumours show >80% TP53 mutations18,19 Interestingly, type I ovarian 
tumours show chemoresistance to conventional chemotherapeutic reagents20-24 
and vice-versa for type II ovarian tumours,21,24 indicating that classification of 
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EOC via molecular subtyping may aid in identifying specific patient groups 
with the more appropriate treatment regimen.25 
   With the advent of microarray-based gene expression profiling technologies, 
high throughput genome-wide analysis of gene expression profiles of 
individual patient ovarian tumour samples allow prediction of patients 
presenting specific gene signatures for clinicopathological features, such as 
early relapse26 and chemotherapeutic response.27 In one such study, gene 
expression profiling of a cohort of serous, endometrioid and mixed serous-
endometrioid ovarian patient samples identified a 14-gene signature list that 
can predict the likelihood of early recurrence with a high degree of accuracy 
(24/28 correct predictions, 86%). Remarkably, of the 19 samples predicted for 
early relapse, 18 patients did eventually relapsed within 21 months post-
treatment.26 Separately, cDNA microarray analysis between two patient groups 
that show either intrinsic chemoresistance or chemosensitivity to platinum-
paclitaxel treatment identified 85 genes differentially expressed between the 
two groups.27 Furthermore, cross-analysis between gene expression profiles of 
patient specimens whom subsequently acquired chemoresistance and the 
intrinsic chemoresistance group identified overlapping genes that would 
indicate to be crucial in mediating chemoresistance.  
   Another study group identified six distinctively novel molecular subtypes 
(C1-C6) from a cohort of 285 ovarian tumour samples, mostly representing 
high-grade serous histological subtype but also includes borderline serous (low 
malignant potential, LMP) and low-grade endometrioid tumours.28 Briefly, 
high-grade serous ovarian tumours mainly clustered into four subtypes (C1, -2, 
-4 and -5) while the less aggressive borderline serous ovarian tumours and low-
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grade endometrioid tumours mainly clustered into subtypes C3 and C6 
respectively. Both subtypes (C3 and C6) displayed low mitotic-index, evident 
by low expression levels of proliferative genes such as cyclin B1 and cyclin-
dependent kinase A-1 (CCNB1, CDC2). Elevated expression of mitogen-
activated protein kinase (MAPK)-related genes were present in subtype C3 
(borderline serous tumours), supporting previous reports of type I low-grade 
serous ovarian tumours carrying BRAF and KRAS mutations.18 Also, subtype 
C6 tumours (low-grade endometrioid) showed higher expression of β-
catenin/LEF/TCF target genes, a hallmark of ovarian endometrioid 
adenocarcinomas (OEA, reviewed in section 1.3: WNT Signalling in EOC). 
Subtypes C1 and -5 tumours (high-grade serous) showed low levels of CD3+ 
tumour-infiltrating T-cells whereas subtypes C2 and -4 displayed higher CD3 
expression levels. Subtype C5 tumours (high-grade serous) showed up-
regulated expression of mesenchymal-associated genes, including homeobox 
genes, down-regulated expression of differentiated ovarian cancer markers 
such as Mucin-1 and Mucin-16 (MUC1 & MUC16), while displaying low 
membrane E-cadherin (CDH1) protein expression. More interestingly, a 
distinctive trend in progression-free survival (PFS) and overall survival (OS) 
was observed: Patients whose tumour specimens fell under C3 (borderline 
serous) and C6 (low-grade endometrioid) subtypes have markedly better 
prognosis while C1 (high-grade serous, low intratumoural CD3+ tumour 
infiltrating T-cells) and C5 (high-grade serous, mesenchymal-like and low 
intratumoural CD3+ tumour infiltrating T-cells) subtypes showed the worst 
prognosis. As such, this study shows the example of using gene expression 
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profiling of ovarian tumours for novel molecular subtype classification to 
better predict clinical outcome.28 
   Another study by The Cancer Genome Atlas group (TCGA) analysed the 
expression profiles of ~12,000 genes from 489 high-grade serous ovarian 
adenocarcinomas (HGSOA) and identified four molecular subtypes within 
HGSOA, namely: i) immunoreactive, ii) differentiated, iii) proliferative and iv) 
mesenchymal.29 Though no significant differences in survival were shown 
among these four subtypes, this study came out with a 193 genes signature list 
capable of predicting overall survival, as further validated on three other 
datasets. Interestingly, patients with tumours carrying BRCA1/2 mutations 
(germline or somatic) had better overall survival as compared to those carrying 
wildtype BRCA1/2 or epigenetically-silenced BRCA1/2, suggesting BRCA1/2 
inactivating mutations act differently from epigenetic silencing mechanisms.29 
In a follow-up study, a patient survival-related gene signature list refined from 
the 193 genes signature list29 resulted in a gene expression-based prognostic 
model (Classification of Ovarian Cancer, CLOVAR).30 Validation of 
CLOVAR on a dataset consisting of 879 HGSOC gene expression profiles 
showed that patient tumours that were double-classified as both ‘poor 
prognosis’ and ‘mesenchymal’ to have the worst outcome, with a median 
overall survival of 23 months and that 63% of patients in this double-
classification, as compared to 23% in all other classifications, to be resistant 
towards platinum-based chemotherapy.30  
   In an independent study to address the heterogeneity of EOC, meta-analysis 
of publicly available microarray gene expression profiles of 1538 EOC samples 
lead to the identification of five distinctive molecular subtypes with different 
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clinicopathological features, namely: Epi-A, Epi-B, Mesenchymal, Stem-A and 
Stem-B.31 Epi-A tumours mostly represent the low-grade, less aggressive 
LMP/ borderline serous subtype with better prognosis while both 
Mesenchymal and Stem-A molecular subtype tumours were mainly of high-
grade with poorer prognosis. Stem-B tumours encompassed all histological 
subtypes that may complement the type I classification of the dualistic model.18 
In vitro validation of genes affecting cell growth in the Stem-A molecular 
subtype eventually identified two microtubule-related genes Tubulin Gamma 
associated Protein Complex 4 (TUBGCP4) and N-Acetyl Transferase 10 
(NAT10) to significantly inhibit cell growth. Of clinical significance, Stem-A 
molecular subtype ovarian cancer cell lines show significant chemosensitivity 
towards tubulin polymerization inhibitors (vincristine and vinorelbine) as 
compared to non Stem-A ovarian cancer cell lines. Furthermore, vincristine 
treatment of the Stem-A cell lines induced apoptosis after 48hr treatment. In 
summary, this study showed that molecular subtyping of EOC is of clinical 
significance in identifying and classifying particular subtypes toward specific 
clinicopathological phenotypes.31 
 
Anoikis:  A role in EOC Metastasis 
   Two hallmarks of cancer include the evasion of apoptosis and acquiring a 
metastatic phenotype.32,33 In EOC progression, ovarian cancer cells must 
overcome an anchorage-independent apoptotic cell death mechanism termed 
‘anoikis’ for survival when suspending in the ascitic fluid, thereby facilitating 
eventual metastatic spread to the peritoneum. 
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   Activating BRAF mutations has been previously reported to protect 
melanoma cells from anoikis via inhibition of pro-apoptotic BH3-mimetics 
BAD (BCL2-associated Agonist of cell Death) and BCL2L11/BIM (BCL2-
like 11).34,35 Interestingly, type I LGSOC commonly carry this activating 
BRAF mutation,13 suggesting that LGSOC are inherently ‘primed’ towards 
anoikis-resistance. Antisense cDNA suppression of the anti-apoptotic effector 
BCL2-like 1 (BCL2L1/ BCL-XL) in HEY ovarian serous carcinoma cells 
induced anoikis upon three-dimensional culturing and the capacity for 
anchorage-independent growth in soft agar was abrogated.36 Furthermore, 
down-regulation of BCL2L1 greatly diminished subcutaneous tumourigenic 
growths in vivo. Array comparative genomic hybridization (CGH) analysis of 
advanced serous EOC identified increased DNA copy number on chromosome 
1q2237 to be associated with elevated expression of the RAB25 small 
GTPase.38 Interestingly, high RAB25 expression correlated with poor 
prognosis. A2780 and T29 ovarian carcinoma cell lines stably overexpressing 
RAB25 augmented anoikis-resistance in suspension culture, while increasing 
anchorage-independent growths in soft agar.38 This was abrogated upon 
RNAi-mediated knockdown of RAB25 in A2780 cells. Furthermore, RAB25 
overexpression concurrently increased AKT phosphorylation and down-
regulated expression of pro-apoptotic effectors BAK (Bcl-2 homologous 
Antagonist/Killer) and BAX (Bcl-2 Associated protein X). Taken together, 
these results suggest that RAB25 down-regulates pro-apoptotic effectors BAK 
and BAX by the PI3K-AKT pathway to promote anoikis-resistance.38 
However, a recent study based on ovarian cancer clinical specimens found no 
	   9	  
significant correlation between elevated immunohistochemical-staining of 
RAB25 and the occurrence of peritoneal metastasis.39 
   Neurotrophic Tyrosine Kinase receptor type 2 (NTRK2/ TrkB) was 
previously reported to be associated with an aggressive phenotype in various 
cancer types and elevated NTRK2 expression was found in the anoikis-
resistant sub-population of OVCAR-3 ovarian serous carcinoma cells.40 
siRNA-mediated knockdown of NTRK2 inhibited PI3K-AKT pathway and 
sensitized OVCAR-3 cells towards anoikis. Furthermore, NTRK2 knockdown 
partially impaired OVCAR-3 cell invasiveness in vitro and smaller tumours 
were formed in vivo. These results show that NTRK2 regulates anoikis and 
tumourigenesis via the PI3K-AKT pathway. Another study showed that 
hepatocyte growth factor (HGF) induced anoikis-resistance in Caov-3 and 
SKOV-3 ovarian carcinoma cells when cultured in suspension. Conversely, 
both siRNA-mediated knockdown and small molecule inhibition of the HGF 
receptor c-MET (MET proto-oncogene receptor tyrosine kinase) abrogated 
anoikis-resistance.41 Interestingly, HGF-stimulation activated both the PI3K-
AKT and ERK1/2-Mitogen-Activated Protein Kinase (MAPK) pathways. Co-
treatment of HGF with either PI3K-inhibitors (wortmannin or LY294002) or 
AKT siRNA or an ERK1/2 inhibitor (PD98059) all abrogated anoikis-
resistance. Furthermore, PI3K inhibitors also inhibited ERK1/2 
phosphorylation. In summary, this study showed a crosstalk between PI3K-
AKT and ERK1/2 MAPK pathways upon induction by HGF to mediate 
anoikis-resistance.41 In a separate study, the use of Foretinib, a small molecule 
multi-kinase inhibitor of c-MET and Vascular Endothelial Growth Factor 
Receptor 2 (VEGFR2) induced cell detachment and subsequent anoikis in 
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Caov-3 cells in a caspase-dependent manner in vitro and reduced the presence 
of SKOV-3 metastatic lesions in vivo.42  
   In another study, the inhibition of ERK1/2 MAPK pathway with U0126 
(small molecular inhibitor of MEK1/2) in IGROV-1 ovarian endometrioid 
carcinoma cells impaired anoikis-resistance, accompanied by an increment in 
the levels of the apoptotic marker cleaved-PARP (Poly ADP-Ribose 
Polymerase).43 Similarly, inhibition of Protein Kinase C (PKC) with 
calphostin C in IGROV-1 cells during suspension culture increased levels of 
cleaved-PARP and caspase-3 activity while the reverse trend was observed 
upon PKC activation with the phorbol ester-based PKC activator PMA. A 
similar pro-anoikic trend was also observed after silencing of αv integrins. 
Furthermore, a slight decrease in ERK1/2 phosphorylation was observed after 
αv integrins knockdown, while the opposite was observed after PMA-induced 
PKC activation. Taken together, these suggest a crosstalk between PKC and 
αv integrins towards ERK1/2 activation for mediating anoikis-resistance in 
IGROV-1 cells.43 
  In vivo passaging of two ovarian serous carcinoma cell lines SKOV-3 and 
HEY generated daughter cells that acquired a more aggressive phenotype, 
termed SKOV-3.ip1 and HEY 1B respectively. Interestingly, these 
transformed cells displayed enhanced anoikis-resistance when cultured in 
suspension,44 further evident by the enhancement of anchorage-independent 
growths of SKOV-3.ip1 cells in soft agar colony formation assays. Of note, 
these transformed cells displayed increased Src kinase activity relative to the 
parental cells, while the ectopic overexpression of Src in OVCAR-5 and 
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OVCA420 ovarian carcinoma cells induced anoikis-resistance when cultured 
in suspension, further showing the role of Src in mediating anoikis-resistance. 
   Following neoplastic formation of the primary tumour, ovarian cancer cells 
eventually shed off from the primary site to suspend in the ascitic fluid within 
the peritoneal cavity. Cells that are anoikis-resistant form aggregates and 
multicellular spheroids. While in suspension, single cells from these 
aggregates and multicellular spheroids may also bud off as precursors,45 acting 
as ‘seeds’ in the ascitic fluid, subsequently re-attaching onto the mesothelial 
lining within the peritoneal cavity.46 Spheroid formation may be initiated from 
monolayer cultures in vitro, with several ovarian cancer cell lines-derived 
spheroids spontaneously budding off thereafter, indicating an alternative route 
towards EOC metastasis.47  
   The attachment of ovarian carcinoma cells onto the mesothelial lining of the 
peritoneal cavity marks a critical step in ovarian cancer progression, indicating 
the onset of invasion through the peritoneum towards organs around the 
abdomen and eventual distal metastasis.  Previous in vitro studies has shown 
that cell-cell and cell-matrix interacting proteins such as CD44 and β1 
integrins to mediate ovarian carcinoma-mesothelial cell interactions.48-52 
Similarly, spheroids from both OVCAR-5 and patient ascites display adhesive 
affinity towards multiple ligands of integrins,53-55 whereby β1 integrins were 
shown to mediate spheroid adhesion onto both ECM components and LP9 
human mesothelial cells. Furthermore, patient-derived spheroids were able to 
disseminate onto live mesothelial cells in vitro, with some invading into the 
mesothelial monolayer.56 Upon re-attachment and dissemination onto the 
mesothelial layer, these cancer cells generate contractile forces on the 
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surrounding mesothelial cells, clearing a passage for subsequent invasion. This 
contractile force is mediated by α5β1-integrin/ myosin II/ talin I between the 
ovarian cancer cells and the mesothelial cells.57 Interestingly, α5 and β1 
integrins mediate in vitro spheroid formation in OVCAR-5 and HEY ovarian 
carcinoma cell lines, whereby inhibition via the respective monoclonal 
antibodies (mAbs) abrogated spheroid formation.53,58 In addition, fibronectin 
and laminin (ligands of integrin receptors) enhanced spheroid formation 
efficiency, further supporting the role of integrins in EOC spheroid 
formation.53 Patient ascitic fluid has been reported to promote spheroid 
formation and cell invasion in vitro, though the study did not find any 
association between the two phenotypes when treated in the same ascitic 
fluid.59 The study identified tribbles pseudokinase 1 (TRIB1) expression to be 
differentially up-regulated in cells treated with ascitic fluid that enhanced cell 
invasiveness. Furthermore, TRIB1 expression was found to be associated with 
poorer patient survival.59 Of importance, spheroids display enhanced 
resistance against both radiotherapy60 and chemotherapeutic reagents61-63 in 
vitro, further complicating treatment strategies. Of note, pathway and network 
analyses of oligonucleotide microarray data of ovarian carcinoma cell lines-
derived spheroids treated with conventional chemotherapeutic agents 
(cisplatin, topotecan and paclitaxel) identified five common networks affected, 
namely i) cell growth/ proliferation, ii) cell cycle, iii) cell death, iv) motility 
and v) metabolism.64 These results would allow for future studies to overcome 
the mechanisms of chemotherapeutic resistance. 
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CHAPTER 1.2 
WNT Signalling: History and Brief Introduction 
   In the mouse, the proto-oncogene int-1 (first common integration site) gene 
was first identified as the proviral integration site of the retroviral mouse 
mammary tumour virus (MMTV) to induce mammary tumourigenesis.65  
Initial work showed int-1 to contain a secretion signal sequence, suggestive of 
a growth factor function.66,67 Subsequent sequencing studies carried out 
separately68,69 identified int-1 to be identical to that of the segment polarity 
gene wingless (wg) in Drosophila, mutants of which display a literally 
wingless phenotype.70,71 As such, int-1 was identified as the first mammalian 
homologue of Drosophila wg. Subsequent confusions in the naming 
nomenclature of int-related genes eventually resulted in the int-1 gene being 
re-named as Wnt1 (Wingless-related MMTV integration site family 1), an 
acknowledgement of the independent studies that resulted in the identification 
of the gene.72 In the human genome, a total of 19 WNT ligands have been 
identified to date, all sharing a highly conserved distribution of 22-24 cysteine 
residues.73,74  
 
Synthesis and Secretion of WNT Ligands 
   WNT ligands are synthesized in the endoplasmic reticulum (ER) and post-
translationally palmitoylated on two conserved residues by the membrane 
bound o-acyltransferase (MBOAT) Porcupine (PORCN),75,76 crucial for 
facilitating proper secretion and ligand-receptor binding.77,78 Palmitoylated 
WNTs are subsequently transported from the trans Golgi network (TGN) to 
the cell surface for secretion by Wntless (WLS), a seven transmembrane WNT 
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protein carrier/ transporter molecule.79-81 Cells expressing mutant WLS 
showed an accumulation of cytosolic WNT, without any WNT ligands 
detectable within the supernatant of the cells.79 Point mutation of a conserved 
serine residue (S209) on WNT3A disrupted proper palmitoylation by PORCN, 
preventing WLS recognition to initiate the transport process.77 Furthermore, 
proper secretions of WNTs by WLS require an acidic vacuolar environment.77 
WLS is subsequently endocytosed and carried back to the endoplasmic 
reticulum (ER)82 through the TGN by the retromer complex through a 
retrograde transport mechanism.83-86 After secretion, WNT ligands may be 
deacylated by the extracellular deacylase Notum, which acts as a regulator of 
homeostasis to render the ligands inactive (see Figure A).87  
 
Figure A: Cartoon depicting the process of WNT synthesis, whereby nascent WNTs 
from the rough endoplasmic reticulum are palmitoylated by Porcupine (PORCN) and 
transported by Wntless (WLS) to the cell surface. Notum acts to maintain 
homeostatic levels of WNT activity, deacylating WNT ligands for inactivation. WNT 
ligands not targeted by Notum proceeds to interact with Frizzled (FZD) receptors on 
the target cell, activating the Wnt cascade. Image from Nusse (2015).88 Reproduced 
with permission from Nature Publishing Group. Refer to Appendix A for the 
copyrights permission granted. 
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   Subsequently, WNT ligands not affected by Notum interacts with their 
respective Frizzled-class receptors (FZD), which are a unique group of seven-
pass trans-membrane G-protein coupled receptors (GPCR) that share a 
homologous N-terminal extracellular cysteine-rich domain (CRD) that 
interacts with WNT ligands. In addition, the C-terminus intracellular domain 
contains a ‘Ser/Thr-Xxx-Val’ motif that interacts with the PDZ domain of the 
cytoplasmic Dishevelled (DVL/Dvl in mammals, Dsh in Drosophila) adaptor 
proteins89 to mediate different branches of the WNT signalling. FZD was first 
identified to be a WNT receptor based on Drosophila models, whereby S2 
cells exogenously expressing fzd2 showed elevated levels of phosphorylated 
armadillo (Drosophila homologue of β-catenin) upon addition of wg.  
Furthermore, immunofluorescence studies showed fzd2 and wg co-
localization in both Drosophila S2 and human 293 cells.90 To date, ten known 
FZD in the human genome have been identified, FZD1-10 (reviewed in 
Schulte, 2010).91 X-ray crystallography between Xenopus Wnt8 and Fzd8 
CRD revealed Wnt8 binding to the Fzd8 CRD on two conserved sites, 
whereby a post-translationally modified palmitoleic acid group on a conserved 
serine residue on the amino-terminus (N-terminus) of Wnt8 inserts into the 
hydrophobic groove within the Fzd8 CRD on one site and hydrophobic 
interactions between the CRD at the carboxyl-terminus (C-terminus) of Wnt8 
and Fzd8 mediates interaction on the second site.78 
 
   WNT signalling is generally sub-divided into two major categories, the 
‘canonical’ or β-catenin-mediated pathway and the ‘non-canonical’ β-catenin-
independent pathway, which is further sub-divided into the planar cell polarity 
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(PCP)/ convergent extension (CE) pathway and the calcium Ca2+ signalling 
pathway, which is beyond the scope of the current study and will not be 
discussed any further. The following will attempt to review the current 
understanding of the β-catenin-mediated and also the PCP/CE pathways 
instead. In the past, WNT ligands have been classified into being either 
canonical or non-canonical. However, numerous recent studies have shown 
that WNT ligands work in a context-dependent manner, with some activating 
the β-catenin-mediated pathway in one system while activating the PCP/CE 
pathway in another system, further adding to the complexity of WNT 
signalling. For a summary of the WNT ligands and FZD receptors involved in 
the various pathways, please refer to Tables 1A and 1B. 
 
WNT Signalling (β-Catenin-mediated) 
   In the absence of WNTs, β-catenin (CTNNB1) is phosphorylated by 
glycogen synthase kinase 3 (GSK3) and Casein Kinase 1 (CK1), which 
together with AXIN (a scaffolding molecule), Adenomatous Polyposis Coli 
(APC) and the protein Dishevelled forms the ‘β-catenin destruction complex’. 
Phosphorylated β-catenin molecules are eventually ubiquitin-tagged for 
proteosomal degradation. During WNT signalling, WNT ligands interact with 
FZD receptors and also with co-receptor Lrp6 (Low-density-lipoprotein 
Receptor-related Protein 6, a single-span transmembrane co-receptor)92,93 via a 
linker region between the N/C-terminus of Wnt ligands and the extracellular 
domain of Lrp6.94,95 As such, Wnt-binding induces a ternary complex 
formation between Fzd-Wnt-Lrp6 while Wnt-Fzd binding induces Fzd-Dvl 
interactions via the PDZ96 and DEP97 domains of Dvl. This allows for Dvl  
	   17	  
Table 1A: Classification of WNT ligands into the respective pathways 
 β-Catenin- TCF/LEF PCP/CE Ca2+ Flux 
WNT1 Gazit et al., 199998 
He et al., 200499 
Korinek et al., 1998100 
Mizushima et al., 2002101 
Papkoff et al., 1996102 
Rhee et al., 2002103 
Shimizu et al., 1997104 
  
WNT2 Basu and Roy, 2013105 
Bravo et al., 2013106 
Fu et al., 2011107 
Gazit et al., 199998 
Goss et al., 2009108 
Karasawa et al., 2002109 
Pu et al., 2009110 
Shi et al., 2007111 
Shimizu et al., 1997104 
Wang et al., 2013112 
Xu et al., 2015113 
You et al., 2004114,115 
Le Floch et al., 2005116 Wayman et al., 
2006117 
WNT2B Cho et al., 2006118 
Kobayashi et al., 2012119 
Li et al., 2015120 
Liu et al., 2012121 
  
WNT3 Gazit et al., 199998 
Lu et al., 2004122 
Shimizu et al., 1997104 
  
WNT3A Boland et al., 2004123 
Gazit et al., 199998 
Nakamura et al., 2003124 
Samarzija et al., 2009125 
Shimizu et al., 1997104 
Yokoyama et al., 2007126 
Simonetti et al., 2014127 Samarsija et al., 
2009125 
Simonetti et al., 
2014127 
WNT4 Guo et al., 2004128 
Lyons et al., 2004129 
Tsaousi et al., 2011130 
Chang et al., 2007131 
Du et al., 1995132 
Maurus et al., 2005133 
Torban et al., 2006134 
 
WNT5A Mikels and Nusse, 2006135 Andre et al., 2012 20136 
Fenstermaker et al., 2010137 
Gao et al., 2011138 
Moon et al., 1993139 
Qian et al., 2007140 
Yamamoto et al., 2007141 
Saneyoshi et al., 
2002142 
Slusarski et al., 
1997143,144 
WNT5B  Hayes et al., 2013145 
Lin et al., 2010146 
Matthews et al., 2008147 
Westfall et al., 2003148 
 
WNT6 Cawthorn et al., 2012149 
Krawetz and Kelly, 2008150 
Li et al., 2014151 
Schmidt et al., 2007152 
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Table 1A (continued): Classification of WNT ligands into the respective pathways 
 β-Catenin- TCF/LEF PCP/CE Ca2+ Flux 
WNT7A Daneman et al., 2009153 
King et al., 2014154 
Posokhova et al., 2015155 
Yoshioka et al., 2012156 
Bentzinger et al., 2013157 
Dabdoub et al., 2003158 
Le Grand et al., 2009159 
van den Berg and Sasson, 
2009160 
 
WNT7B Arensman et al., 2014161 
Daneman et al., 2009153 
Pietilä et al., 2011162 
Posokhova et al., 2015155 
Wang et al., 2005163 
Yu et al., 2009164 
Fenstermaker et al., 2010137 
Zheng et al., 2013165 
 
WNT8A Kimura-Yoshida et al., 
2005166 
So et al., 2013167 
  
WNT8B Kelly et al., 1995168,169 
Kim et al., 2002170 
Lee et al., 2006171 
  
WNT9A Guo et al., 2004128 Curtin et al., 2011172 
Dougherty et al., 2013173 
Kan and Tabin, 2013174 
 
WNT9B Boivin et al., 2015175 
Carroll et al., 2005176 
Karner et al., 2011177 
Kiefer et al., 2012178 
Lan et al., 2006179 
Karner et al., 2009180  
WNT10A Cawthorn et al., 2012149 
Hsu et al., 2012181 
  
WNT10B Cawthorn et al., 2012149 
Li et al., 2011182 
Wend et al., 2012183 
Wend et al., 2013184 
Yoshikawa et al., 2007185 
  
WNT11 Tao et al., 2005186 
Ye et al., 2011187 
Bai et al., 2014188 
Du et al., 1995132 
Hayes et al., 2013145 
Heisenberg et al., 2000189 
Kim et al., 2008190 
Marlow et al., 2002191 
Tada and Smith, 2000192 
Ouko et al., 
2004193 
WNT16 Guo et al., 2004128 
Wergedal et al., 2015194 
Kan and Tabin, 2013174  
WNT16B Mazieres et al., 2005195 
Moveraré-Skrtic et al., 
2014196 
Sun et al., 2012 2012197 
Teh et al., 2007198 
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Table 1B: Classification of FZD receptors into the respective pathways 
 β-Catenin- TCF/LEF PCP/CE Ca2+ Flux 
FZD1 Doi et al., 2014199 
Flahaut et al., 2009200 
Gao and Wang, 2006201 
Liu et al., 2001202 
Neumann et al., 2010203 
Planutis et al., 2013204 
Trowe et al., 2012205 
Wang et al., 2005163 
Zhang et al., 2012206 
Hung et al., 2014207 
Yu et al., 2010208 
 
FZD2 Li et al., 2008209 
Verkaar et al., 2009210 
Gujral et al., 2014211 
Kadzik et al., 2014212 
Li et al., 2013213 
Lin et al., 2010146 
Yu et al., 2010208 
Yu et al., 2012214 
Ahumada et al., 
2002215 
Ma and Wang, 
2006216 
Zhou et al., 
2012217 
FZD3  Chai et al., 2015218 
Cizelsky et al., 2014219 
Hua et al., 2014220,221 
Lyuksyutova et al., 2003222 
Montcouquiol et al., 2006223 
Onishi et al., 2013224 
Simonetti et al., 2014127 
Simonetti et al., 
2014127 
FZD4 Birdsey et al., 2015225 
Jin et al., 2011226 
Tickenbrock et al., 2008227 
Ye et al., 2011187 
Bian et al., 2014228 
Descamps et al., 2012229 
Yu et al., 2010230 
 
FZD5 Liu et al., 2008231 Lee and Heur, 2014232 
Slater et al., 2013233 
Arderiu et al., 
2014234 
FZD6  Cantilena et al., 2012235 
Devenport and Fuchs, 2008236 
Golan et la., 2004237 
Guo et al., 2004238 
Hua et al., 2014221 
 
FZD7 Chakrabarti et al., 2014239 
Kim et al., 2008240 
Mei et al., 2014241 
Zhang et al., 2013242 
Asad et al., 2014243 
Bentzinger et al., 2013157 
Kim et al., 2008190 (JCB) 
Kraft et al., 2012244 
Yu et al., 2012214 
Yuan et al., 2015245 
Zhang et al., 2013242 
 
FZD8 Albers et al., 2013246 
Bourhis et al., 201094 
Bravo et al., 2013106 
Kim et al., 2002170 
Miao et al., 2015247 
Yin et al., 2013248 
Moon et al., 1993139  
FZD9 Fujimoto et al., 2009249 
Karasawa et al., 2002109 
Wang et al., 2009250 
  
FZD10 Galli et al., 2014251 
Terasaki et al., 2002252 
Wang et al., 2005163 
Fukukawa et al., 2009253  
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recruitment of the Axin-Gsk3 complex via a homologous DIX domain 
between Dvl- Axin.254,255 As such, recruitment of the Axin-Gsk3 complex by 
Dvl within close proximity of Lrp6 facilitates Gsk3 phosphorylation of 
multiple P-P-P-S/T-P proline- rich motifs on the cytoplasmic domain of 
Lrp6,256 thereby promoting Lrp6-Axin interactions257-259 that disrupt proper 
formation of the β-catenin destruction complex.260 It should also be noted that 
CK1 has also been implicated in Lrp6 phosphorylation to mediate Wnt 
pathway activation as well, reportedly in a membrane-bound manner 
independent of Axin and GSK-3β.257 As such, unphosphorylated β-catenin 
molecules accumulate in the cytoplasm, eventually translocating to the cell 
nucleus by a yet unclear mechanism to activate Tcf/LEF transcription factors 
(reviewed in Clevers & Nusse, 2012).261 Some of the target genes include: c-
MYC,262 cyclin D1 (CCND1),263,264 fibronectin (Gradl et. al, 1999),265 matrix 
metalloproteinase (MMP) 1/ 7/ 14,266-269 Slug/ SNAI2,270 survivin271,272 and 
ATP-binding Cassette G2 (ABCG2) transporter efflux pump.273 For an 
overview of the β-catenin-mediated pathway, refer to Figure B.  
 
WNT Signalling (Non β-catenin-mediated/ β-catenin-independent) 
   Planar cell polarity (PCP) describes the pathway regulating the axial 
positioning of a body plane; aligning cells/structure/organ/body with reference 
to the plane towards specific orientations, resulting in coherent group of cells 
with uniformed polarity. In Drosophila, this involves two subsets of PCP-
related genes expressed asymmetrically in either the proximal- or distal-end at 
the cellular level (refer to Table 1). Furthermore, gradient expression of Fat 
(FT), Dachsous (DS) and Four-jointed (FJ) provide cues to promote FT-DS 
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heterodimer towards a particular orientation. These asymmetric expression 
patterns stimulate downstream effector molecules, providing positional cues to 
orientate cells or tissue towards a particular polarity (reviewed in Bayly & 
Axelrod, 2011).274One such example is the development of the Drosophila 
wing, whereby hair cuticles orientate uniformly towards the distal end 
(reviewed in Adler, 2002).275 
           
Figure B: Overview of WNT/β-catenin-mediated pathway. Image from Nusse, 
2012.276 
 
Table 2: Asymmetric distribution of core components of the Frizzled/PCP pathway 
Proximal Distal 
Drosophila Vertebrate Drosophila Vertebrate 
Flamingo (fmi) CELSR1/2 Flamingo 
(fmi) 
CELSR1/2 
Prickle (pk) PRICKLE1/2/3 Frizzled (fz) Frizzled  
(FZD1-10) 








 Diego (dgo)  Ankyrin repeat 
domain 6 
(ANKRD6) 
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   Drosophila carrying mutant frizzled (fz) display defective cuticular polarity 
with hair cuticles being non-uniformly patterned along the proximal-distal axis 
in multiple regions including the wings and legs, suggesting the involvement 
of Wnt signalling in mediating PCP.277-279 In mus musculus, presence of either 
Wnt7a or Wnt-antagonists Sfrp1 (Secreted Frizzled Related Protein 1) or Wif1 
(Wnt Inhibitory Factor 1) inhibited proper orientation of hair cell stereociliary 
bundles in the sensory epithelium of the cochlea158 while Ryk-/- mice (receptor 
related to tyrosine kinase, a Wnt receptor tyrosine kinase with a Wnt 
Inhibitory Factor/WIF-domain),280,281 Ptk7 mutant mice (Protein tyrosine 
kinase 7, a pseudokinase) and Wnt5a-/- embryos all displayed a similar 
phenotype.140,282,283 Knock-out of the Wnt receptor Frizzled-6 (Fzd6) has been 
shown to regulate hair-patterning growth independent of Wnt/β-catenin 
signalling,238 displaying hair whorl patterning similar to that of Fz-/- 
Drosophila wings, demonstrating the conservation of PCP-pathway genes 
between invertebrates and vertebrates. Furthermore, the asymmetric 
localization of Fzd6 in the embryonic epidermis of mice was shown to 
mediate hair follicle polarity during development.236 
   Convergent extension (CE) describes the intercalation of cells towards a 
single plane (convergence) that results in a collective directional elongation 
out towards the perpendicular plane (extension) during development, usually 
involving the convergence of cells in the mediolateral and dorsal-ventral axes 
and extension of the anterior-posterior axis. Examples of CE movements 
include mesodermal cells along the archenteron resulting in notochord 
formation during Xenopus and zebrafish (danio rerio) gastrulation and 
neurulation,284 and elongation of presomitic mesodermal cells during 
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neurulation in mice.285 Of note, the genes regulating PCP in invertebrates also 
regulate CE in vertebrates, showing that PCP and CE share a conserved 
pathway across species and more importantly, that cell polarity mediates the 
onset of motility.286,287 During the collective migration of cells observed 
during CE, migratory cells at the leading edge adopt a front-back planar 
polarity, whereby active protrusions at the frontal edge and a retractive area at 
the back are formed to mediate motility (reviewed in Mayor and Theveneau, 
2014).288 Wnt/PCP mediate CE upon Wnt ligand binding to Fzd receptors, 
recruiting Dishevelled (Dsh/ DVL) and Dishevelled Associated Activator of 
Morphogenesis 1 (Daam1, a Formin-homology containing cytoplasmic 
adaptor protein) via both PDZ and DEP domains289,290 to activate RhoA and 
Rac1 small GTPases to induce cytoskeletal remodeling, acquiring cell polarity 
to mediate cellular migration. Rac1 induces actin polymerization required for 
the formation of active protrusions (lamellipodia, filopodia and invadopodia) 
to facilitate motility at the leading edge while RhoA regulates Rho associated 
kinase (Rok2) activation to induce stress fiber formation and actomyosin 
contractility at the back-end through cell-cell ‘contact inhibition of 
locomotion’ mechanisms.288 The involvement of Wnts in convergent 
extension movements during vertebrate development was demonstrated after 
overexpression of Wnt5A in Xenopus embryos resulted in a neural ectoderm 
defective phenotype (incomplete anterior neural tube closure), manifesting 
itself with the compression of the anterior-posterior body axis and widening of 
the medial-lateral axis, appearing  ‘shorter and fatter’ than wildtype 
embryos.139 Furthermore, Wnt5A overexpressing Xenopus embryos did not 
undergo morphogenetic elongation after activin-mediated mesoderm 
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induction139 while antagonism of Wnt5A and Fzd8 disrupted convergent 
extension during Xenopus gastrulation.291 A subsequent follow-up study in 
Xenopus identified overexpression of either Wnt4 or Wnt11 to induce a similar 
phenotype ex vivo.132 In developing mice embryos, graded expression of 
Wnt5a in the palate was observed in an anterior-posterior distribution and 
mesenchymal palatal cells migrated directionally towards the Wnt5a 
gradient.292 Wnt5a-/- embryos displayed a defective migratory phenotype in the 
palatal mesenchyme, resulting in cleft palate.292 Furthermore, Wnt5a-/- 
embryos impaired CE movements, evident by shortened anatomical features 
including body length and tail during anterior-posterior extension, forelimbs at 
the distal end with loss of digital differentiation, frontal-nasal development 
and cochlear duct extension.136,138,140 Morpholino-induced silencing of Wnt5b 
in zebrafish embryos impaired posterior extension accompanied by dense 
somitic distribution.146 Furthermore, expression of mutant Dishevelled (Dsh) 
in Xenopus Keller explants disrupted cell polarity and stability of cell 
protrusions, subsequently impairing regular convergent extension movements 
during gastrulation and neurulation.293 Interestingly, this defective phenotype 
was shown to be mediated by the PDZ and DEP but not the DIX domains of 
Dsh,293 implicating the former two domains to mediate Wnt/PCP pathway, as 
has been previously reported.294,295 In addition, phosphorylation of Dsh is 
mediated by Wnt11 and expression of a dominant-negative Wnt11 (dnWnt11, 
C-terminus truncation) impaired Dsh phosphorylation, accompanied by 
disruption of convergent extension during Xenopus gastrulation.192 Rescue of 
the phenotype was achieved by expressing a Dsh-ΔN (N-terminus truncation) 
construct comprising of the PDZ and DEP but not the DIX domains, 
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demonstrating Wnt-induced CE movements is β-catenin-independent192 as the 
DIX domain is required for interacting with Axin to disrupt subsequent β-
catenin degradation.254,296,297 Similarly, loss-of-function mutation of Wnt11 in 
zebrafish impaired regular convergent extension during gastrulation, even 
resulting in cyclopia.189 Furthermore, constitutive activation of β-catenin (ΔN 
β-catenin) in Wnt11-/- embryos failed to rescue the phenotype, neither did 
expression of a dominant-negative Tcf-3 induce the Wnt11-/- phenotype,189 
providing further evidence that CE movements is not mediated by Wnt/β-
catenin pathway. In addition, morpholino-silencing of Ryk displayed the same 
phenotype as Wnt11-/- in zebrafish282 while impairing neural tube closure and 
Keller sandwich explant elongation during embryonic development in 
Xenopus.190 Ptk7 mutant embryos of both mice and zebrafish displayed 
hallmarks of PCP-defects: shortened anterior-posterior body length and 
extended medio-lateral body axis145,283,285 accompanied by shorter and wider 
posterior notochord.145,285 Interestingly, Ptk7 potentiated the Wnt/PCP 
pathway in zebrafish embryos, enhancing the phenotypes induced by  Wnt5b 
or Wnt11 overexpression.145 Furthermore, chuzhoi (Chz) mutant mice carry a 
splicing mutation in Ptk7, resulting in an addition of three amino acids that 
disrupted proper function.298 Ptk7Chz/Chz homozygous embryos display 
impaired PCP/CE movements, evident by severe neural tube closure defects 
and mis-orientation of stereociliary hair bundles within the cochlear 
epithelium.298  Also, embryos of double heterozygous mice carrying either, 
Ptk7-/+;Vangl2Lp/+, Ror2-/-;Vangl2Lp/+ or Ryk-/+;Vangl2Lp/+ mutations displayed 
enhanced severity in neural tube closure defects as compared to the single 
heterozygous mutants (Lp: Looptail transgenic mice carrying Vangl2 G1391A 
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point mutation, resulting in a serine → asparagine mutation at amino acid 464 
of the protein).138,282,283 Taken together, these results further show that Ptk7, 
Ror2 and Ryk mediate PCP and CE through the Wnt/PCP pathway.138,282,283 
Similarly, transgenic mice models carrying mutations in several of the PCP 
homologs disrupted mesodermal CE movements during neurulation, 
displaying severe defects in neural tube closure.299-304 
                                         
Figure C: Overview of the PCP pathway. Image taken from Nusse, 2012.276 
 
Other WNT co-receptors mediating PCP 
   ROR2 (Receptor tyrosine kinase-like orphan receptor 2) is a single 
transmembrane receptor that was first identified through cDNA PCR 
screening of a human neuroblastoma cell line (SH-SY5Y) with an intracellular 
tyrosine kinase domain305 and a conserved extracellular cysteine-rich domain 
(CRD) homologous to that of the FZD receptors.305,306 Subsequent in vitro 
binding and immunoprecipitation assays identified this CRD of Ror2 to bind 
to Wnt5a and Fzd2 in rats (rattus norvegicus, note that rat Fzd2 is homologous 
to human Fzd5),307 Wnt5a, Wnt8 and Wnt11 in Xenopus,308 Wnt11 in 
zebrafish (danio rerio)188 and Fzd7 in mus musculus,309 demonstrating Ror2 to 
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act as a receptor/ co-receptor for Wnt ligands. Perturbed fore- and hindlimb 
cartilage growths at the distal end displayed by Ror2 homozygous-deletion 
mutant mice (Ror2-/-)310,311 is due to the disruption of Wnt5a-induced Ror2-
Vangl2 heterodimer receptor complex formation and subsequent Vangl2 
phosphorylation by casein kinase I delta (CKIδ) to induce PCP/CE directional 
growths.138 Dominant-negative Ror2 in zebrafish (dnRor2) lacking the 
cytoplasmic domain displayed defective CE movements during gastrulation, 
evident by shorter embryos in the anterior-posterior axis, wider somites in the 
mediolateral axis and cyclopia,188 which could be partially rescued by 
exogenous introduction of either Dsh or RhoA.188 Of interest, several in vivo 
studies have shown similar phenotypes between either Ror2-/-/Wnt5a-/- or 
Ror2-/-/Wnt11-/- models138,188,292,307,312 while Ror2 siRNA-silencing impaired 
NIH3T3 cellular response to Wnt5a-induced cell migration/ wound healing in 
vitro.313 Ror2 mediates Wnt5a-induced activation of JNK/AP-1 to promote 
filopodia formation for polarized cell motility by forming a Wnt5a-Fzd7-Ror2 
complex that promotes Dvl2 phosphorylation and polymerization, which 
recruits Rac1 to induce cytoskeletal reorganization via the JNK/AP-1 
pathway.309,312 Furthermore, the C-terminus proline-rich domain (PRD) at the 
cytoplasmic end of Ror2 recruits Filamin A alpha (Flna, an actin-binding 
protein involved in cytoskeletal remodeling) to initiate the formation of active 
protrusions (filopodia and lamellipodia) at the leading edge to facilitate cell 
motility.313,314 In addition, Ror2 can activate both Rho small GTPase and JNK 
pathway via Wnt5-a induced Ror2-Vangl2 receptor complex formation.138 
Furthermore, Ror2-/- palatal cells displayed defective cell migration in palate 
development even in the presence of Wnt5a ex vivo.292 In contrast, ectopic 
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expression of Ror2 in Xenopus and danio rerio inhibited CE movements 
during gastrulation, neurulation and anterior-posterior elongating 
growths.188,307,308 
 
   RYK (receptor-like tyrosine kinase) was identified in mice by selective PCR 
amplification of receptor tyrosine kinase-related domains315,316 while the 
human homolog was sequenced from a hepatoma cDNA library shortly 
after.317,318 RYK is a single transmembrane receptor carrying a Wnt Inhibitory 
Factor (WIF) extracellular domain319 and a catalytically inactive tyrosine 
kinase domain in the cytoplasmic region with a PDZ-domain at the carboxyl-
terminus (reviewed in Halford and Stacker, 2001).280 The WIF-domain of Ryk 
mediates binding to several Wnt ligands, including: Wnt1,320,321 -3,322,323 -
3a,320 5a,190,281,282 -5b146 and -11190,282 while the PDZ domain has been 
reported to interact with Dvl/Dsh in mice320 and Xenopus.190 
   Ryk-/- mice displayed similar phenotypes to PCP-impairment, including 
craniofacial defects, impaired anterior-posterior extension and cleft 
palate.281,324 Ryk was subsequently identified to mediate Wnt-induced 
repellent signals during corticospinal tract axon guidance of neonatal mice.321 
Similarly, Ryk mediated Wnt3-induced retinal ganglion cell axonal 
repulsion322 and Wnt5a-indcued repulsion of callosal axons to guide 
contralateral crossing.281  
   Interestingly, Ryk acts as a co-receptor with Fzd7 to mediate Wnt11-induced 
endocytic-internalization of Fzd7-Dsh and Dsh hyperphosphorylation in 
Xenopus during CE movements in the dorsal marginal zone (DMZ).190 
Expression of Ryk morpholino disrupted Dsh internalization and promoted 
	   29	  
Dsh co-localization to the cell membrane.190 Also, Ryk mediates RhoA and 
JNK activation, translocating RhoA to the cell membrane,190 supporting 
another later study whereby Ryk activates RhoA small GTPase in CHO-K1 
cells.282 
   Furthermore, treatment of SN4741 murine cells with a RYK WIF-domain 
human monoclonal antibody (RWD1 mAb) impaired Wnt5a-induced Dvl2/3 
phosphorylation in vitro and antagonized Wnt5a-induced axonal neurite 
outgrowths by murine embryonic cortical neurons.325 However, it should be 
noted that Ryk has previously been reported to mediate Wnt3a/β-catenin 
pathway to induce murine neurite outgrowths by forming a ternary complex 
between Wnt3a and Fzd8 through the extracellular WIF-domain and with Dvl 
through the cytoplasmic PDZ-domain to promote Tcf transcriptional 
activity.320 Furthermore, Ryk siRNA-silenced murine dorsal root ganglion 
cells did not respond to Wnt3a-induced neurite outgrowths ex vivo.320 
   Antisense morpholino silencing of either Wnt5b or Ryk in zebrafish embryos 
induced similar phenotypes with impaired anterior-posterior extension and 
wider somites in the mediolateral axis indicative of disrupted CE movements, 
suggesting Ryk to mediate Wnt5b-induced CE.146 Furthermore, double 
knockdown of Wnt5b and Ryk enhanced CE defective phenotypes as 
compared to just single knockdown, indicating Wnt5b-Ryk genetic interaction 
in zebrafish during gastrulation.146 Genetic interactions between Wnt 11 and 
Ryk were also shown with double knockdown zebrafish embryos displaying a 
more severe ocular developmental defect.282 
   Wnt5b-Ryk expression induced polarized active protrusion formation 
(lamellipodia and filopodia) in embryonic hypoblast cells, which was 
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abolished when a dominant-negative Ryk (dnRyk) was introduced.146 
Interestingly, the protrusions of Ryk-expressing cells were oriented away from 
Wn5b expression, indicating that Wnt5b acts as a directional cue for Ryk-
expressing cells.  
   RYK interacts with VANGL2 through the PDZ domain at the cytoplasmic 
region in HEK293T cells282 and co-immunoprecipitation between Ryk-Vangl2 
was enhanced in the presence of Wnt5a.136 Furthermore, Vangl2 protein levels 
increased in the presence of either Wnt5a or Ryk, suggesting that Ryk 
mediates Vangl2 stability through Wnt5a.136 
 
WNT Signalling in Cancer and Stem Cells 
   The proto-oncogenic role of WNT was established when MMTV proviral-
integration into Wnt1 (int1) promoter region drove mammary tumour 
formation in mice.65 Subsequently, APC germline mutations were reported in 
patients with familial adenomatous polyposis (FAP),326,327 while CTNNB1 
mutations in other cancers, including endometrioid ovarian cancer, showed 
varying frequencies328-333 (reviewed in Bell, 2005)334. These mutations on 
conserved N-terminus serine/ threonine residues confer resistance against 
GSK-3β-mediated phosphorylation, protecting β-catenin from proteosomal 
degradation.335,336 
   The involvement of Wnt/ β-catenin pathway in maintaining stemness was 
demonstrated when non-functional, unpalmitoylated Wnt-3A diminished self-
renewal of hematopoietic stem cells (HSC),75 while the constitutive activation 
of β-catenin maintained self-renewal.337 Furthermore, activation of WNT 
signalling by GSK-3 inhibition in human embryonic stem cells (hESC) 
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maintained pluripotency.338 β-catenin has also been implicated in maintaining 
colonic progenitor cells by activating c-MYC to suppress p21-mediated G1 
cell cycle arrest and differentiation.339 In addition, the Wnt target gene 
leucine-rich-repeat-containing G-protein-coupled receptor 5 (Lgr5) is a 
marker for intestinal stem cells in the small intestinal and colonic crypt 
base.340 Activation of the Wnt pathway in Lgr5+ intestinal stem cells via 
conditional-deletion of Apc transformed these cells to become tumourigenic, a 
proof-of-concept for cancer stem cells.341 Previously, overexpression of LGR5 
has been reported in ovarian cancer as well.342 More recently, expression of 
Lgr5+ cells was found on the OSE and oviduct of the mouse ovaries.343 In vivo 
lineage tracing of Lgr5+ ovarian stem/ progenitor cells of both embryonic and 
neonate mice were shown to undergo consistent clonal expansion to 
regenerate and maintain the ovarian surface epithelium (OSE) during pre-
puberty.343 Furthermore, adult Lgr5+ cells displayed variable rates of 
expansion post-puberty, with a higher density of Lgr5+ cells located around 
either sites of rupture during ovulatory repair or the corpus luteum, providing 
evidence that the pool of Lgr5+ stem/ progenitor cells’ recruitment to sites of 
ovulatory rupture mediated regenerative healing.343 
   β-catenin-mediated activation of Survivin expression confers anti-apoptotic 
resistance, maintains stem cell survival in the basal colonic crypt and has been 
suggested to promote stemness in cancers.271 Survivin is also highly expressed 
in leukemic stem/ progenitor cells344 and confers drug-resistance.345 The 
exogenous co-expression of Slug (SNAI2) and sex determining region Y box 
9 (SOX9) in differentiated mammary luminal cells was able to revert these 
luminal cells back into a mammary stem cell state.346 Furthermore, induced 
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co-expression of SNAI2 and SOX9 augmented micrometastases in MCF7 
breast cancer cells. Interestingly, β-catenin is known to positively regulate 
transcriptional activation of both SOX9347 and Slug/ SNAI2.270 Heterogeneous 
β-catenin expression in colorectal cancer (CRC) demonstrates the functional 
multiplicity of β-catenin: membranous β-catenin expression in well-
differentiated/ epithelial-like cells of the tumour core mediates cellular 
adhesion within the adherens junctions, while predominant nuclear β-catenin 
expression in the dedifferentiated/ mesenchymal-like cells at the invasive front 
indicates activated Wnt signalling.348,349 Nuclear β-catenin expression at the 
invasive front activated the expression of L1 cell adhesion molecule (L1CAM) 
and laminin γ2 (LAMC2), both of which mediates cellular motility and 
invasion.350,351 In cancer progression, invasive cancer cells from the primary 
site undergo a morphological transformation from a differentiated, epithelial 
phenotype into a more de-differentiated/ mesenchymal phenotype, a process 
described by the developmental process epithelial-mesenchymal transition 
(EMT). Upon completion of the metastatic cascade, these invasive cancer cells 
revert back to the epithelial morphology through mesenchymal-epithelial 
transition (MET) to drive tumour growth in the secondary site.352 β-catenin 
has been reported to induce EMT353 and to promote a more stem-like 
phenotype in primary cultures.354 Taken together, the distinctive expression 
profile of nuclear β-catenin at the invasive front led to the suggestion that Wnt 
signalling is involved in mediating cancer progression between stationary and 
migrating cancer stem cells (SCS/ MCS cells).355  
   The WNT/PCP pathway has also been shown to mediate cancer progression. 
Wnt5a overexpression in gastric cancer cells promoted cell migration in vitro 
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by activating focal adhesion kinase (FAK) and Rac while RNAi-mediated 
silencing of Wnt5a inhibited cell migration by disrupting the turnover of 
paxillin focal adhesions.356 Furthermore, in vitro Wnt5a-treatment of MDA-
MB-231 triple negative breast cancer (TNBC) cells activated RHOA to 
stimulate cell migration in a WNT5A-DVL2-DAAM1-dependent manner, 
while constitutive activation of DAAM1 further enhanced cell migration in 
MCF-7 breast cancer cells.357 Similarly, exogenous overexpression of WNT5A 
in both T21PT (atypical ductal hyperplasia) and T21NT (ductal carcinoma in 
situ) cells increased cellular migration in transwell migration assays while 
shRNA-mediated knockdown of RHOA diminished this increment.358 
Furthermore, stable knockdown of VANG1 curtailed cell invasion in both 
WNT5A-transfectants, further implicating the WNT/PCP pathway in mediating 
cell motility and invasion in breast cancer.  
   The BRAF serine/ threonine kinase proto-oncogene is frequently mutated 
(BRAFV600E/K) in melanomas, resulting in constitutive activation. These 
BRAF-mutant melanomas initially respond to BRAF-inhibitors (BRAFi) such 
as PLX4270, though subsequent acquired resistance has been associated with 
WNT5A up-regulation while siRNA-mediated knockdown of WNT5A 
impaired PLX4720-resistance.359 Furthermore, WNT5A expression activated 
the PI3K/AKT pathway while suppressing WNT/β-catenin pathway, 
suggesting that the mechanisms involved in acquiring BRAFi-resistance is β-
catenin-independent. 
   In another study, exosomes secreted by breast cancer associated fibroblasts 
(CAF) induced formation of active protrusions in MDA-MB-231 cells that 
enhanced cell motility via autocrine WNT11-mediated PCP pathway, whereby 
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WNT11 secreted by MDA-MB-231 cells tethers to the exosomes secreted 
from CAF, eventually being endocytosed by MDA-MB-231 cells to activate 
autocrine PCP pathway.360 PCP core components displayed asymmetric 
distribution during Wnt11-mediated PCP signalling, whereby Fzd6 and Dvl1 
expression co-localized at the leading edge of cell protrusions while Pk1 and 
Vangl1 co-localized at the non-protrusive rear cortex. Of relevance, siRNA-
mediated knockdown of each of these PCP-core genes, including Wnt11 
abrogated cell protrusions and significantly reduced cell motility even when in 
the presence of CAF. Furthermore, shRNA-mediated knockdown of Pk1 in 
MDA-MB-231 cells impaired micrometastases formation when injected in 
mice mammary fat pads (MFP). 360 
   In synovial sarcoma, FZD10 mediates the PCP pathway through activating 
the DVL2/3-RAC1-JNK cascade.253 Ectopic overexpression of FZD10 in 
synovial sarcoma cell lines induced actin reorganization through RAC1 
activity (GTP-bound) and JNK1/2 phosphorylation while siRNA-mediated 
knockdown of either DVL2/3 suppressed RAC1 activity and inhibited JNK1/2 
phosphorylation. Furthermore, FZD10 overexpression inhibited RHOA-
mediated actin stress fiber formation, demonstrating that FZD10 in synovial 
sarcoma mediates RHAOA and RAC1 activity in a mutually exclusive 
manner. Interestingly, FZD10 overexpression in synovial sarcoma cell lines 
promoted anoikis-resistance in soft colony formation assays while siRNA-
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FZD7 in Cancer 
   FZD7 (FzE3) expression was initially identified in poorly differentiated 
human squamous cell esophageal carcinoma with high metastatic potential.361 
Ectopic overexpression of FZD7 (FzE3) promoted cytoplasmic and nuclear β-
catenin accumulation in KYSE150 esophageal carcinoma cells,361 indicating 
the capability of FZD7 (FzE3) in promoting WNT/β-catenin signalling. A 
comparative genomic hybridization (CGH) study of 46 sporadic and familial 
ovarian cancer samples showed one of the minimal region of interest most 
commonly amplified is within chromosome 2q32.1-34.362 Interestingly, this 
region includes the locus of two FZD genes: FZD5 (2q33.3) and FZD7 (2q33). 
cDNA microarray analysis of primary cultures of EOC and OSE revealed 
~43% (9/21) of EOC cultures overexpress FZD7, while FZD7 transcript 
expression in  most OSE cultures were lower.363 While screening through the 
transcript expression profile of EMT-related genes on a panel of ovarian 
cancer cell lines (SGOCL-series), Frizzled-7 (FZD7) expression was 
identified to be up-regulated in SKOV-3 ovarian cancer cells when cultured as 
spheroids in suspension.243 Previously, it has been reported that the formation 
of spheroids from primary cultures resulted in the enrichment of stem-like/ 
progenitor populations,364,365 whereby single cells dissociated from non-
adherent mammospheres formed colonies of mixed lineages (ductal and 
myoepithelial) at a higher frequency than freshly dissociated mammary 
tissues.365 Interestingly, FZD7 was reported to regulate hESC pluripotency by 
regulating POU5F1/OCT4, a key component involved in maintaining stem 
cell pluripotency.366 Withdrawal of the self-renewing factor Fibroblast Growth 
Factor 2 (FGF2) from culture media induced stem cell differentiation, 
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accompanied by a marked reduction in FZD7 transcript expression.367 
Inhibition of FZD7 in hESC through either short hairpin RNA (shRNA) or a 
FZD7-specific fragment antigen binding protein (FZD7-Fab) down-regulated 
expression of pluripotency markers NANOG and POU5F1/OCT4, indicating a 
role that FZD7 has in maintaining hESC pluripotency. Furthermore, pre-
treatment of FZD7-Fab to hESC cells prior to mouse Wnt3a stimulation 
(highly homologous to WNT3) reduced TOP-GFP fluorescence readout, 
suggesting WNT3 to be a ligand for FZD7.367 cDNA microarray analysis 
showed FZD7 to be overexpressed in both hESCs and human embryonal 
carcinoma cells (hECCs).368 Furthermore, FZD7 transcript expression in 
hECC was up-regulated in the presence of Wnt-3A.369 Another study reported 
that the knockdown of FZD7 in hECC reduced proliferation.370 In contrast, a 
plasma membrane-based study reported FZD7 to be differentially expressed in 
hESC but not hECC.371 
   cDNA microarray analysis of nasopharyngeal carcinoma (NPC) in two 
studies both identified FZD7 to be differentially expressed in the tumour 
compartment.372,373 Expression was further validated using in situ 
hybridization (ISH) staining.373 Interestingly an association was found 
between EBV-infection and expression of genes in WNT signalling, 
including: FZD7, CREB-binding protein (CREBBP) and casein kinase II β 
(CSNK2β), suggesting a potential role of WNT signalling in mediating EBV-
infection.373 In a microarray study of breast cancer patient samples, FZD7 was 
more highly expressed in the triple negative breast cancer (TNBC) subtype. 
FZD7 short hairpin RNA-mediated (shRNA) knockdown in MDA-MB-231 
cells (TNBC-subtype) reduced cell proliferation in vitro and formed smaller 
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tumours in vivo.374 Short interfering RNA (siRNA)-mediated knockdown of 
FZD7 in colorectal cancer (CRC) cell lines reduced invasion and formed less 
liver metastases in vivo.375,376 Of clinical relevance, CRC patients with higher 
FZD7 expression showed poorer survival rates.376 Similarly, SK-CO-1 
colorectal adenocarcinoma cell line ectopically expressing FZD7 ecto-domain 
(C-terminus truncated FZD7, FZD7ΔC) induced EMT-like morphological 
changes and abrogated tumour formation in severe combined immunodeficient 
(SCID) mice.377 shFZD7-mediated knockdown in LIM1863-Mph (human 
CRC cell line) maintained a mesenchymal phenotype with reduced 
proliferative rates and abrogated carcinoid formation in vitro by inhibiting 
mesenchymal-epithelial transition (MET).378 
   In melanoma, FZD7 acts as a receptor for WNT5A to mediate β-catenin-
independent signalling to mediate drug resistance against BRAFi PLX4720.359 
siRNA-mediated knockdown of FZD7 reduced cell viability and abrogated 
colony and melanosphere formation in vitro in two melanoma cell lines (A375 
and MEL624). In addition, loss of FZD7 chemosensitized these two cell lines 
towards PLX4720 by disrupting FZD7-mediated PI3K/AKT activation of 
proliferative/ survival signals. 
   FZD7 was found to be overexpressed in hepatocellular carcinoma (HCC) in 
both transcript and protein levels.379 Introduction of a dominant negative 
construct of FZD7 into primary HCC cultures reduced β-catenin 
phosphorylation and nuclear accumulation, demonstrating that FZD7 can 
activate the β-catenin pathway in HCC.379 WNT3 was subsequently reported 
to be the ligand responsible for activating FZD7 in HCC.240 Interestingly, 
stable over-expression of WNT3/FZD7 transformed non-tumourigenic hepatic 
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cells, acquiring enhanced capabilities in proliferation, migration, invasion and 
anchorage-independent growths in vitro, though the transformed cells failed to 
form tumours in vivo,380 suggesting that WNT3/FZD7-mediated WNT 
signalling to be an early driver of HCC development. Pharmacological 
inhibition of FZD7 amino-terminus-DVL protein-protein interactions via a 
small molecule peptide RHPD-P1 induced β-catenin degradation and eventual 
apoptotic cell death in Huh7 HCC cells in a PKCδ-dependent manner in 
vitro.381 Furthermore, tumourigenic impairment was observed after injection 
of RHPD-P1 into SV40-TAg mice predisposed of hepatocarcinogenesis, 
demonstrating RHPD-P1 potency against HCC both in vitro and in vivo.381 
Similarly, a small molecule inhibitor (FJ9) antagonising FZD7 carboxyl-
terminus-DVL1 PDZ domain protein-protein interactions was previously 
reported to inhibit β-catenin/ TCF transcriptional activity in HCT116 CRC 
cells.382 Furthermore, FJ9 also inhibited tumourigenic growths of LOX 
melanoma cells, H460 and H1073 non-small cell lung carcinoma (NSCLC) 
cells in vitro and H460 cells in vivo.382 Competitive inhibition of FZD7 by 
sFZD7 (soluble extracellular domain of FZD7) sensitized HCC cells towards 
doxorubicin treatment, showing that combinatorial treatment of a conventional 
chemotherapeutic agent with a WNT inhibitor (sFZD7) is possible.383  
   In samples of Wilm’s Tumour, certain cell populations were reported to 
undergo apoptosis when treated with a FZD7 antibody.384 These cells, when 
xenografted into mice models showed reduced cell proliferation, evident by 
smaller tumour growths with weaker Ki-67 immunostaining. The authors also 
reported that FZD7-treatment within this cell population eliminated their 
ability to form spheroid in suspension, an indication of loss of self-renewal in 
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the stem/ progenitor population, suggesting that FZD7 plays a role in 
maintaining the stem/ progenitor-like properties of the cancer cells. Recently, 
one FZD7-based recombinant antibody, OMP18R5 (Vantictumab, developed 
by OncoMed Pharmaceuticals Inc.) showed significant reduction in tumour 
growths in xenograft models, especially in pancreatic, breast and lung tumour 
models.385 However, this antibody also interacts with four other FZD 
receptors, namely FZD1/2/5/8. Phase 1 dose escalation trial against solid 
tumours began in May 2011 but was temporarily halted as 13% of patients 
receiving treatment displayed ‘on-target mild-to-moderate bone-related 
adverse effects’ (Oncomed Pharmaceutical website). Recruitment is currently 
underway for phase 1b clinical trials of Vantictumab in combination with 
other standard-of-care chemotherapeutic agents: stage IV pancreatic cancer 
(with nanoparticle albumin-bound (Nab)-Paclitaxel and Gemcitabine), 
previously treated non-small cell lung carcinoma (NSCLC, with Docetaxel) 
and metastatic breast cancer (with Paclitaxel).  These clinical trials will be 
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CHAPTER 1.3 
WNT Signalling in Epithelial Ovarian Cancer (EOC) 
Deregulated β-catenin Expression in EOC 
   In a small pilot study, immunohistochemical analysis of 40 primary 
epithelial ovarian tumours showed that a majority of the endometrioid subtype 
(5/6) displayed β-catenin cytoplasmic and nuclei staining.386 DNA sequencing 
of β-catenin (encoded by the CTNNB1 gene) in these 5 endometrioid ovarian 
lesions (one borderline tumour and four stage I and II carcinomas) showed 
activating missense mutations within exon 3 in 3/5 of the endometrioid 
ovarian lesions with nuclei expression. Interestingly, the two codons mutated 
(S37 and T41) fall within the consensus phosphorylation site by glycogen 
synthetase kinase-3 (GSK-3), a serine/ threonine kinase.335,387,388 These 
mutations disrupted the GSK-3 consensus recognition sites on β-catenin, 
preventing regular GSK-3 phosphorylation-induced degradation of β-catenin, 
eventually resulting in aberrant β-catenin-mediated WNT signalling in this 
subtype of ovarian cancer. In a follow-up study on 69 stage I and II ovarian 
carcinomas, 11 samples showed nuclear β-catenin staining, of which 9 were 
of the endometrioid subtype, the other 2 being serous.389 Among these 9 
endometrioid subtypes, 7 showed β-catenin gene missense mutations within 
the exon 3 region. Unfortunately, β-catenin sequencing analysis was not 
carried out on the 2 serous subtypes. Separate studies carried out by various 
groups subsequently identified β-catenin activating mutations around the 
exon 3 region, between codons 32 to 45.328,329,386,389-397 All studies found only 
missense mutations in the endometrioid subtype, except for one study that  
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Table 3: List of β-catenin (CTNNB1) mutations (exon 3: GSK-3 phosphorylation 
site) in Ovarian Cancer 
Codon Mutation Histological Subtype Reference 
D32G  
(GAC → GGC) 
Borderline endometrioid tumour394 
Endometrioid carcinoma389,395 
D32H 
(GAC → CAC) 
Endometrioid carcinoma329 
D32Y  
(GAC → TAC) 
Borderline endometrioid tumour394 
Endometrioid carcinoma329,389,392,393 
S33A 
(TCT → GCT) 
Endometrioid carcinoma397 
S33C  
(TCT → TGT) 
Borderline endometrioid tumour394 
Endometrioid carcinoma328,329,389,391-393,395-398 
Ovarian microcystic stromal tumour (MCST)399 
S33F 
(TCT → TTT) 
Borderline endometrioid tumour394 
Endometrioid carcinoma328,391,396,397 
S33P 
(TCT → CCT) 
Endometrioid393 
S33Y 
(TCT → TAT) 
Endometrioid carcinoma329,397 
G34E 
(GGA → GAA) 
Endometrioid carcinoma329,391 
G34R  
(GGA → CGA) 
Endometrioid carcinoma329,397 
G34R 
(GGA → AGA) 
Endometrioid carcinoma397 
G34V 
(GGA → GTA) 
Endometrioid carcinoma328,329,395,397 
H36P 
(CAT → CCC) 
Endometrioid carcinoma397 
S37A  
(TCT → GCT) 
Endometrioid carcinoma397  
TOV112D ovarian endometrioid adenocarcinoma cells329 
S37C  
(TCT → TGT) 
Borderline endometrioid tumour386 
Endometrioid carcinoma328,329,386,391-393,395,397  
Mucinous carcinoma390 
S37F 
(TCT → TTT) 
Borderline endometrioid tumour394 
Endometrioid carcinoma386,392,393,397 
S37Y 
(TCT  TAT) 
Endometrioid carcinoma395 
A39T 
(GCC → ACC) 
Endometrioid carcinoma393 
T41A  
(ACC → GCC) 
Endometrioid carcinoma386,390,392,395,396 
T41I 
(ACC → ATC) 
Endometrioid carcinoma390,393,397 
S45P 
(TCT → CCT) 
Endometrioid carcinoma396 
S45Y 
(TCT → TAT) 
Endometrioid carcinoma329 
S45S (Silent mutation) 
(TCT → TCG) 
Endometrioid carcinoma (squamous metaplasia)391 
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found a missense mutation in one tumour of mucinous histological subtype 
(S37C, refer to table 3).390 Of note, no interstitial deletions were identified on 
β-catenin in ovarian tumours. Among the studies cited here, the frequency of 
β-catenin gene missense mutations in the endometrioid subtype varies 
between  ~10 to 55% (refer to table 4).328,329,386,389-393,395-397 It should be noted 
that most of the ovarian endometrioid tumours carrying activating mutations 
of CTNNB1 displayed strong nuclear and membranous β-catenin staining, 
suggesting that these activating mutations help tumour cells to offset 
availability of β-catenin for either nuclear translocation or adherent junctions 
formation.328 However, one study reported that endometrioid tumours with 
squamous metaplasia and nuclear β-catenin staining showed reduced 
membranous staining intensity when compared to surrounding ovarian 
carcinoma cells without nuclear β-catenin staining.391 A similar observation 
was made in ovarian serous adenocarcinoma samples (nuclear accumulation 
with weaker membranous staining).400 Interestingly, patients with ovarian 
endometrioid tumours carrying nuclear β-catenin expression correlated with a 
better prognosis, either relapse-free survival389,393,401 or better overall patient 
survival, suggesting β-catenin to be a potential prognostic biomarker in 
ovarian endometrioid cancer.389 In addition, it was observed that many low 
malignant potential (LMP) endometrioid tumours carry β-catenin missense 
mutations, suggesting that β-catenin may drive ovarian tumourigenesis from 
LMP precursors.386,389 Consistent with these observations, ovarian 
endometrioid tumours with nuclear β-catenin staining are generally 
characterized to be well differentiated329 (with regions of squamous 
metaplasia displaying nuclear β-catenin)391,402, of low-grade and in the early  
	   43	  
                 
Table 4: Frequency of nuclear staining of β-catenin and CTNNB1 gene  
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                 Table 4 (continued): Frequency of nuclear staining of β-catenin and CTNNB1   
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§ Low-grade (Grades 1 & 2) ovarian endometrioid tumours 
‡ High-grade (Grade 3) ovarian endometrioid tumours 
 
† β-catenin (CTNNB1) mutation and nuclear staining was only found in the 
endometrioid compartment 
* Less than 5% of total cells stained positive for nuclear β-catenin 
∆ This study takes into account of both nuclear and cytoplasmic immunostaining as 
positives 
# Ovarian endometrioid tumour of borderline malignancy 
 
stages.393,398 However, it should be highlighted that a contrasting trend was 
observed in separate studies on ovarian serous tumours: both low- and high-
grade tumours with nuclear β-catenin staining showed shorter patient survival 
as compared to tumours without nuclear β-catenin expression. Also, majority 
of the serous tumours with nuclear β-catenin immuno-reactivity were 
classified as high-grade tumours (11/48, 23%).406,407 Interestingly, a separate 
study found nuclear β-catenin staining in 25/36 (69%) of ovarian serous 
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carcinoma samples tested, with none of the samples analyzed carrying β-
catenin gene mutations.156 Of note, 7 of these samples were also used in a 
separate panel for WNT7A in situ hybridization analysis. 5/7 (71%) of these 
samples showed strong positivity for WNT7A and nuclear β-catenin, 
suggesting that an alternative route for activating WNT/β-catenin pathway in 
serous carcinomas.156 In ovarian mucinous carcinoma, the frequency of 
nuclear β-catenin varies between 4-23%,390,401,402,405 though only one 
missense mutation in the β-catenin gene has been reported.390 As such, the 
only consensus conclusion for β-catenin activating missense mutations in 
EOC is that it is histotype-specific, predominantly found in OEAs of low 
grade and early stage, with better prognosis. 
   One observation that arose from these studies was that not all tumours with 
nuclear β-catenin immunostaining carried β-catenin mutations. This would 
indicate the involvement of other components of the WNT/β-catenin 
signalling pathway that can contribute to β-catenin constitutive activation. 
Aside from β-catenin itself, mutations have been reported in other genes 
encoding the β-catenin destruction complex, including APC, AXIN1 and 
AXIN2.329,395 Briefly, a primary ovarian endometrioid adenocarcinoma (OEA) 
with nuclear β-catenin harbouring wildtype β-catenin was identified to carry 
two truncating nonsense mutations (Arg554Stop and Arg1114Stop) of the 
APC gene.329 These premature stop codons effectively inactivated APC 
functions, promoting stabilized β-catenin accumulation. In another study, 
APC expression was found to be absent in 46/113 (41%) primary and 
metastatic serous ovarian tumour biopsies. Interestingly, 3 samples stained for 
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nuclear β-catenin, all devoid of APC expression.408 However, it should be 
pointed out that the other 43 samples negative for APC expression has no 
detectable nuclear β-catenin expression. This would indicate that either serous 
ovarian carcinomas seldom express β-catenin, or β-catenin phosphorylation 
might not solely depend on the β-catenin destruction complex itself. In an 
epigenetic study, APC promoter hypermethylation was present in 22% of 
invasive ovarian carcinoma (5/23) but not in benign cystadenomas.409 
Interestingly, APC promoter hypermethylation was only present in serous, 
mucinous and clear cell histological subtypes but not in the endometrioid 
subtype. 
   AXIN1 truncating nonsense mutation (Lys416Stop) was identified in a 
primary OEA sample.329 However, this OEA only expressed weak 
cytoplasmic β-catenin but not nuclear β-catenin. Similarly, one OEA sample 
with missense mutation (Thr520Pro) showed membranous β-catenin 
staining.395 In contrast, a human OEA-derived cell line (MDAH2774) 
carrying an AXIN1 missense mutation (Val555Ile) stained positively for 
nuclear β-catenin and displayed enhanced TCF transcriptional activity. This 
amino acid change falls within the AXIN1: β-catenin interaction domain, 
thereby preventing proper formation of the β-catenin destruction complex.329 
In another primary OEA sample, an interstitial deletion of a guanine (G) base 
resulted in a frameshift mutation at codon 665 of AXIN2.329 This stable form 
of mutant AXIN2 was previously reported in colorectal cancer to enhance 
TCF-dependent transcription activity, indicating the mutant to be dominant-
negative.410 Of note, the frequency of these mutations is relatively low as 
compared to β-catenin mutations. 
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   In an animal study, mice OSE cells with aberrant β-catenin expression were 
generated by conditional deletion of β-catenin (Ctnnb1Δ(ex3)/+).411 Pre-tumoural 
nests of cells with nuclear β-catenin expression were detected in the ovarian 
bursa and OSE of 12 week-old mice. No pre-tumoural nests were observed in 
control mice. Interestingly, upregulated expression of the tumour suppressor 
Phosphate Tension and homolog (Pten) was observed in the pre-tumoural 
lesions. Half of these β-catenin mutant mice developed tumours between 8 – 
12 months, of which most were of the undifferentiated histological subtype, 
positively staining for the mesenchymal marker vimentin. 5/6 mice examined 
displayed epithelial glands, a hallmark of OEAs. To determine if Pten 
mediated the latent tumourigenic phenotype, mice with aberrant β-catenin 
expression in the OSE with Pten deletion (Ctnnb1Δ(ex3)/+;PtenΔ/Δ) were 
generated. OSE from these mice developed gross tumours within 6 weeks, as 
compared to 8 – 12 months in the Ctnnb1Δ(ex3)/+ mice. In summary, the result 
from this animal study demonstrates a proof-of-concept that dysregulated 
Wnt/β-catenin signalling drives ovarian tumourigenesis formation when de-
voided of Pten/PI3K signalling.411 Another finding from this study was that 
tumours derived from both Ctnnb1Δ(ex3)/+ and Ctnnb1Δ(ex3)/+;PtenΔ/Δ mice showed 
elevated phospho-ribosomal protein S6 Kinase (pS6K) expression, suggesting 
the Mechanistic Target of Rapamycin (MTOR) pathway to be involved as 
S6K is a downstream target of mTOR. Interestingly, human OEAs with 
nuclear β-catenin expression were found to stain strongly for MTOR, 
pMTOR and pS6K, indicating activated MTOR pathway in these human OEA 
cells. To further test this, Ctnnb1Δ(ex3)/+;PtenΔ/Δ ovarian tumour cells were 
allotransplanted into non-obese diabetic/ severe combined immunodeficient 
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(NOD/SCID) mice and received rapamycin treatment for 12 weeks. 
Rapamycin-treated mice showed significantly smaller tumour growths 
compared to vehicle control-treated mice. Furthermore, ovarian tumour cells 
from rapamycin-treated mice had a lower mitotic index and increased Caspase 
3 (Casp3) activation, indicative of reduced proliferation and active apoptosis 
respectively. In addition, pS6K expression was abrogated in the rapamycin-
treated group, further supporting that β-catenin-induced activation MTOR 
drove murine ovarian tumourigenesis.411 
 
WNT Target Genes in EOC 
   To better understand how the WNT/β-catenin signalling pathway drives 
ovarian carcinogenesis, several studies sought to identify target genes 
regulated by the pathway. Based on previously reported β-catenin target 
genes in other cancer models,263,264,268,412-414 comparison of transcript 
expression between OEAs with aberrant β-catenin expression and intact β-
catenin regulation identified significantly upregulated expression of five 
target genes: i) Cyclin D1 (CCND1), ii) Matrix Metalloproteinase 7 (MMP7), 
iii) Peroxisome Proliferator-Activated Receptor delta (PPAR-δ), iv) Connexin 
43 (CX43) and v) Immunoglobulin Transcription Factor 2 (ITF-2).403 
Validation via immunohistochemical staining of CCND1, MMP7 and ITF-2 
in the OEAs showed a significant correlation between nuclear β-catenin 
immunoreactivity and higher protein expression levels of CCND1, MMP7 or 
ITF-2.403,414 More importantly, statistical significance was found in the 
expression of the three target genes between OEAs with deregulated β-catenin 
and OEAs carrying wildtype β-catenin. These results were supported by an 
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immunohistochemical-based study, whereby CCND1 expression was found to 
be present in 3/8 (37.5%) of OEAs with nuclear β-catenin staining. It was also 
found that patients co-expressing MMP7 and nuclear β-catenin had a better 
survival outcome than patients expressing MMP7 alone (mean patient follow-
up of 8.5 years).393 Subsequent oligonucleotide gene expression microarray 
analysis between the two groups of OEAs found 81 candidate target genes 
regulated by the WNT/β-catenin/TCF pathway, of which 7 were previously 
reported to be direct β-catenin gene targets in other models.415 Validation via 
transcript expression profiling of the top five candidate target genes with the 
highest upregulation, including: CCND1, Cystatin 1 (CST1), Endothelin 3 
(EDN3), Fibroblast Growth Factor 9 (FGF9) and Stratifin (SFN/14-3-3σ), all 
showed significant correlation with the microarray data.415 Furthermore, 
putative TCF-binding sites were identified between 500 to 2000 basepairs 
(bp) upstream of the transcription start sites (TSS) of both CST1 (four sites) 
and EDN3 (three sites). Mutations of all these sites carried out separately in 
HEK293 cells with constitutive β-catenin activation nullified both CST1 and 
EDN3 gene expression respectively, indicating that these TCF-binding sites 
act as proximal promoters for both CST1 and EDN3, both of which can be 
regulated by β-catenin/TCF transcription factors. In addition, stable 
expression of a dominant-negative TCF (dnTCF) construct in TOV112D 
(OEA cell line carrying a constitutive β-catenin mutation329) reduced 
luciferase reporter activity of both CST1 and EDN3, further showing that 
these two genes are direct targets of the β-catenin/TCF signalling.415 
Following up on this study, the same group subsequently showed that both the 
transcript and protein expression of FGF9 to be upregulated in OEAs with 
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defective β-catenin regulation.416 A similar trend was also observed in two 
OEA cell lines with deregulated β-catenin expression: MDAH2774 and 
TOV112D. Moreover, GSK-3β inhibition via lithium chloride (LiCl) 
treatment in OVCA420 serous ovarian carcinoma cells with wildtype β-
catenin increased FGF9 transcript expression. Furthermore, TOV112D-
dnTCF-4 cells (TOV112D cells stably expressing a dominant-negative TCF-4 
construct) showed a marked reduction in FGF9 transcript expression.416 
Interestingly, stable knockdown of FGF9 via short hairpin RNA (shRNA) in 
TOV112D OEA cells abrogated anchorage-independent growth in soft agar, 
indicating FGF9 protects TOV112D cells from undergoing anoikis. However, 
it should be noted that FGF9 was previously reported to be preferentially 
expressed in OSE than in EOC cultures.363 
   Using microarray gene expression profiling as before,415 gene expression 
profiles of two sets of data were compared i) OEAs with wildtype β-catenin 
against OEAs carrying β-catenin activating mutations, ii) human embryonic 
kidney HEK293 cells stably expressing a β-catenin mutant construct 
(HEK293CTNNB1-S37A) against HEK293 cells stably expressing the empty 
vector with GFP construct (HEK293GFP-control). From these analyses, two more 
β-catenin/TCF candidate target genes were identified: Fibroblast Growth 
Factor 20 (FGF20) and Dickkopf WNT signalling inhibitor 1 (DKK1).417 
Subsequent validation work carried out in the HEK293 cells included 
chromatin immunoprecipitation (ChIP) and analysis of proximal promoter 
regions upstream of the respective genes’ TSS for TCF-binding sites. β-
catenin immunoprecipitates from chromatin of HEK293CTNNB1-S37A cells were 
enriched for DNA regulatory sequences for both FGF20 and DKK1, as 
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compared to chromatin from HEK293GFP-control cells. Also, TCF-binding sites 
were identified as proximal promoters upstream of the TSS for both FGF20 
(two sites) and DKK1 (four sites). Co-transfection of a constitutively active β-
catenin mutant construct with a luciferase reporter construct containing the 
putative promoter regions of either FGF20 or DKK1 in HEK293 cells showed 
increased luciferase activity from both FGF20 and DKK1 reporters. This 
luciferase reporter activity was lost upon co-transfecting an inhibitor of β-
catenin and T-cell factor (ICAT) construct. Complete loss of DKK1 reporter 
luciferase activity was also achieved when all putative TCF-binding sites 
were either deleted or point-mutated via site-directed mutagenesis.417 
Interestingly, DKK1 expression was found to be downregulated >20-fold in 
an oxaliplatin-resistant derivative of A2780 ovarian carcinoma cell line.418  
   Following up on the microarray analysis of OEA samples carried out 
previously,415 Muscle Segment homeobox-2 (MSX2) overexpression was 
found in OEA samples with defective WNT signalling regulation. Subsequent 
validation showed MSX2 transcript expression to be nine-fold higher when 
compared against OEA samples with wildtype β-catenin regulation.419 
Immunohistochemical staining showed 13/17 (76%) of OEA samples with 
defective WNT signalling regulation to stain positively for MSX2 (moderate 
to strong intensity). Of the 13 OEA samples with intact WNT signalling 
regulation, only one sample was shown to stain positively for MSX2.419 Also, 
murine OEA tumours derived from APC -/PTEN - background showed >200-
fold higher Msx2 transcript expression than murine KRAS mut/PTEN - driven 
OEA tumours, suggesting that aberrant Wnt signalling in mice activates Msx2 
expression. Furthermore, activation of WNT signalling either by i) treatment 
	   52	  
with recombinant mouse Wnt3a in human OSE cell line IOSE80 or ii) 
inhibiting GSK-3β via the small molecule inhibitor SB216763 in a human 
OEA-derived cell line MDAH2774, both increased MSX2 transcript 
expression after treatment. In addition, TOV112D-dnTCF-4 cells (TOV112D 
cells stably expressing a dominant-negative TCF-4 construct) showed a 
marked reduction in both the transcript and protein expression of MSX2. Nine 
consensus TCF/LEF binding sites were located around the MSX2 gene locus, 
suggesting MSX2 to be a direct target gene of β-catenin/TCF/LEF 
transcription. ChIP of TOV112D cells against TCF4 antibody showed 
chromatin DNA to be enriched for three of the MSX2 TCF/LEF consensus 
binding sites, confirming MSX2 to be a direct β-catenin target gene.419 
TOV112D and TOV21G cells stably expressing short hairpins of MSX2 
displayed in vitro growth impairment. Anchorage-independent growth was 
also impaired after MSX2 knockdown in TOV112D cells, evident by fewer 
colonies formed in soft agar. Subcutaneous injection of TOV112D cells after 
MSX2 knockdown into mice formed significantly smaller tumours than the 
control after 3 weeks, demonstrating that MSX2 acts as an oncogene in EOC. 
Ectopic overexpression of MSX2 in IOSE80 cells promoted in vitro cell 
invasion through Matrigel-coated transwells. Furthermore, in vivo cell 
invasion assay showed PEO4 human ovarian carcinoma cells ectopically 
overexpressing MSX2 displayed enhanced invasiveness into chick 
chorioallantoic membrane, mimicking stromal invasion. In summary, MSX2 
was shown to be a direct target oncogene for β-catenin/TCF/LEF 
transcription, evident by influencing cell proliferation, anchorage-independent 
growth, in vivo tumourigenicity and cell invasion.419 
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   In a study investigating the enhanced chemoresistance of spheroid-forming 
ovarian tumour initiating cells (OTIC), transcript expression of ATP-binding 
Cassette G2 (ABCG2), an efflux transporter mediating drug-resistance was 
shown to be up-regulated in spheroids derived from SKOV-3 and HEY A8 
ovarian serous carcinoma cell lines.273 Interestingly, either siRNA-mediated 
down-regulation of β-catenin (CTNNB1) or ectopic expression of the 
dominant-negative TCF (dnTCF) construct down-regulated ABCG2 
expression and chemosensitized SKOV-3 and HEY A8 OTICs towards 
cisplatin and paclitaxel. Moreover, siRNA-silencing of ABCG2 also displayed 
chemosensitivity. Furthermore, suppressed TOPflash luciferase activities (β-
catenin-TCF reporter construct) were shown in cells carrying the dnTCF 
construct. Taken together, the suppression of β-catenin/TCF down-regulated 
ABCG2 expression, indicating ABCG2 to be a gene target of β-catenin/TCF 
transcription.273 Microarray analysis of spheroid and monolayer cultures of 
both IGROV-1 and SKOV-3 ovarian carcinoma cell lines identified 
expression of Aldehyde Dehydrogenase 1A1 (ALDH1A1), a stem cell marker, 
to be up-regulated in ovarian carcinoma spheroids.420 Pathway network 
analysis identified ALDH1A1 to be a central node directly connected to 
CTNNB1. Moreover, spheroids showed up-regulated β-catenin and ALDH1A1 
transcript expression, further accompanied by increased TCF/LEF promoter 
activity. Conversely, ALDH1A1 expression was down-regulated after β-
catenin siRNA silencing, indicating ALDH1A1 to be involved in the WNT/β-
catenin pathway. In addition, amplicons of the TCF/LEF binding motif 
specific to the ALDH1A1 promoter region was amplified out from chromatin 
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DNA immunoprecipitated by a β-catenin antibody, proving ALDH1A1 to be a 
direct target of the β-catenin/ TCF/LEF transcription complex.420 
 
WNT Regulators in EOC 
   Several studies also reported identifying regulators of the WNT/β-catenin 
pathway in EOC.105,400,421-424 Frequently Rearranged in Advanced T-cell 
lymphomas 1 (FRAT1) and Axin has previously been reported to share the 
same binding region to GSK-3, suggesting that FRAT1 can negatively 
regulate WNT/β-catenin signalling by competing with Axin for binding.425-427 
In a separate immunohistochemical-based study on tissue microarrays (TMA) 
of human EOC samples, significant correlation was found between FRAT1 
overexpression and accumulation of cytoplasmic/ nuclear β-catenin 
expression within the same samples, especially in the serous subtype.400 It 
should be noted that no molecular studies were provided in this study. In other 
previous studies, the disruption of E-cadherin/ β-catenin adhesion complex 
increased subcellular localization of β-catenin, thereby promoting WNT/β-
catenin activity.428,429 This would implicate E-cadherin to be a regulator of the 
WNT/β-catenin pathway. In particular, this disruption was induced by 
interaction with collagen type I in pancreatic cancer cells.429 During ovarian 
cancer metastasis, ovarian cancer spheroids/ multicellular aggregates reattach 
to the mesothelial peritoneal cavity lining via integrin-collagen type I 
mediated adhesion.54-57 To test if this interaction disrupts E-cadherin/ β-
catenin adhesion to activate WNT/β-catenin signalling, OVCA429 and 
OVCA433 ovarian cancer cell lines were cultured on collagen type I surface 
and E-cadherin distribution was analyzed thereafter via immunofluorescence 
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staining.421 Junctional E-cadherin localization was significantly redistributed 
to the cytoplasm after culturing in collagen type I surfaces. This interaction 
was mediated by integrins α2, α3 and β1, but not α5 and αv.421 This in turn 
lead to an accumulation of nuclear of β-catenin (validated by immunoblotting 
of collagen type I-treated nuclear extracts), suggesting active WNT/β-catenin 
signalling. In addition, immunoblotting of whole cell lysates against active β-
catenin (dephosphorylated β-catenin at Ser37 and Thr41) showed an increase 
in the active form after integrin β1 engagement. Interestingly, GSK-3 was 
inactivated (Ser 9 phosphorylation) after integrin β1 interaction, suggesting 
that cytoplasmic β-catenin was not targeted for degradation by GSK-3. 
Furthermore, TOPflash luciferase reporter assays showed increased luciferase 
readout after integrin β1 engagement, indicating activation of β-
catenin/LEF/TCF transcription. This was further validated by increased 
transcript expression of several WNT target genes. 
   Pituitary homeobox 2/ Paired-like homeodomain 2 (PITX2) is a 
transcription factor of the bicoid homeodomain family that has been 
previously reported to regulate left/ right asymmetry determination in 
vertebrates.430 PITX2 has also been reported to act as an effector and 
regulator of the Wnt/β-catenin pathway to mediate cell proliferation during 
development.431,432 Interestingly, PITX2 overexpression was reported in high-
grade ovarian cancer.433 Furthermore, overexpression of PITX2 in mouse 
models enhanced ovarian cancer cells proliferation, with an increased 
expression of WNT/β-catenin target genes CCND1 and c-MYC.433 Microarray 
analysis showed upregulated PITX2 and WNT5A expression by ~20-fold in an 
oxaliplatin-resistant derivative of A2780 ovarian carcinoma cell line.418 Taken 
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together, PITX2 may play a role in mediating WNT/β-catenin signalling in 
driving ovarian carcinogenesis and mediating drug resistance. In a separate 
study using ChIP-on-Chip assays, wildtype PITX2 in the human epithelial 
ovarian adenocarcinoma cell line SKOV-3 was shown to bind to the promoter 
region of several WNT genes, including WNT2, -2B, -5A, -6 and -9.105 Further 
validation using promoter-driven luciferase-reporter constructs in Chinese 
Hamster Ovary cells (CHO) showed enhanced WNT2 and WNT5A promoter 
activity (10 and 8-fold respectively) in the presence of PITX2, indicating 
PITX2 to regulate the expression of WNT2 and WNT5A. Moreover, SKOV-3 
cells carrying overexpressing constructs of each of the three PITX2 isoforms 
(PITX2A, -B, -C) all showed increased transcript levels of four WNT ligands: 
WNT2, -5A, -6 and -9. Conversely, RNA-silencing of PITX2 in SKOV-3 cells 
via small-interfering RNA (siRNA) markedly reduced transcript expression of 
the four WNT ligands. Interestingly, an increase in the pool of activated β-
catenin (unphosphorylated) was observed in SKOV-3 cells overexpressing 
PITX2 isoforms. Furthermore, these cells showed increased transcript 
expression of β-catenin target genes CCND1 and c-MYC. A similar finding 
was made when SKOV-3 cells were treated in PITX2-conditioned-media 
enriched for the PITX2 isoforms. Also, PITX2 overexpression unexpectedly 
reduced the expression of several Frizzled receptors (FZD2, -3, -4, -9) and 
low density lipoprotein related protein co-receptors (LRP5/6), suggesting that 
PITX2 may act as a negative feedback-loop regulator of the WNT/β-catenin 
pathway. 
   Transcript of FILamin A Interacting Protein 1-Like (FILIP1L, formerly 
called Downregulated in Ovarian Cancer 1, DOC1) is preferentially expressed 
	   57	  
in human OSE (HOSE) cells but not in ovarian carcinoma cell lines.434 
Previously, FILIP1L was shown to inhibit endothelial cell migration435 and 
downregulated FILIP1L expression via promoter hypermethylation in ovarian 
cancer cell lines induced cell invasiveness,436 demonstrating FILIP1L to be an 
inhibitor of cell invasion. In a study to better understand the mechanistic 
pathway that FILIP1L employs to inhibit cell invasion and metastasis, ES2 
ovarian carcinoma cells stably expressing a doxycycline-inducible FLIP1L-
mCherry tagged construct were orthotopically injected into ovaries of mice, 
which generated aggressive tumours with the presence of lung 
micrometastases within 14 days.422 Upon doxycycline treatment, cell invasion 
was greatly diminished, resulting in significant reduction of micrometastases 
formed. Interestingly, a similar phenotype was observed between 
doxycycline-treated FILIP1L clones and FILIP1L clones treated with a pan-
MMP inhibitor (GM6001) in the absence of doxycycline. This shared 
phenotype would suggest that FILIP1L might target MMP expression to cause 
impaired cell invasion. Of note, MMPs are known to be WNT/β-catenin 
target genes.403 True enough, transcript expressions of MMP3, -7, -9 were 
found to be downregulated in the FILIP1L clones. This was further validated 
by immunofluorescence and immunoblotting experiments. However, FILIP1L 
clones invasiveness dramatically increased upon transfection of a MMP9 
cDNA construct, indicating that the FILIP1L-induced impairment of cell 
invasiveness may be overcome with ectopic expression of MMP9. 
Furthermore, FILIP1L clones-derived tumours showed downregulated 
transcript expression of six WNT ligands, including WNT2, -3A, -4, -5A, -7A 
and -11. This was further demonstrated when treatment of FILIP1L clone 
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cultures with WNT3A induced MMP3, -7 and -9 transcript expression, 
whereas MMP transcript expression decreased upon co-treatment with 
doxycycline and WNT3A. This confirms that FILIP1L does indeed down-
regulate WNT ligand expression. In addition, FILIP1L clone cultures showed 
reduced TOPflash luciferase activity when treated with WNT agonists (pan-
WNT agonist and GSK-3β inhibit, BIO), as compared to the uninduced 
control. Also, immunoblots of FILIP1L clones showed higher levels of 
phosphorylated β-catenin, while immunofluorescence staining showed 
reduced levels of nuclear β-catenin as compared to the uninduced controls. 
Taken together, these results indicate that FILIP1L inhibits WNT/β-catenin 
signalling pathway, thus reducing expression levels of WNT target genes, 
such as MMPs, resulting in the impairment of cell invasiveness of ovarian 
cancer cells to prevent metastasis. 
   In the β-catenin/TCF transcription complex, two nuclear co-factors Pygopus 
family PHD finger (PYGO) and B-cell CLL/ Lymphoma-9-Like (BCL9L), 
were identified to be required for mediating proper β-catenin/TCF 
transcription activity.437-440 In a study, immunohistochemical analysis of one 
OSE cell line, three EOC cell lines and 125 patient tumour samples 
representing all histological subtypes showed nuclear PYGO2 
immunoreactivity in all three EOC cell lines and majority of EOC tumour 
samples (113/118, 96%) but not in the OSE cell line or in all seven benign 
tumour samples.441 Interestingly, only 8 EOC tumour samples showed nuclear 
immunoreactivity for both β-catenin and PYGO2, suggesting that PYGO2 
may also act independently of β-catenin. Antisense-mediated knockdown of 
PYGO2 in four EOC cell lines (SKOV-3, OVCAR-3, TOV21G and 
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TOV112D) all reduced cell proliferation over a 72hr period. Conversely, 
rescue experiments by exogenous expression of PYGO2 in PYGO2-knocked-
down SKOV-3 and OVCAR-3 serous ovarian carcinoma cell lines restored 
cell proliferation rates similar to that of control conditions. Strikingly, 
parental SKOV-3, OVCAR-3 and TOV21G (clear cell-derived, β-catenin-
null) cells showed negligible TOPflash luciferase activity, indicating that 
PYGO2 possess functional effects in EOC even in the absence of β-
catenin/TCF transcriptional activity. Furthermore, in vitro soft agar colony 
formation assays of SKOV-3 cells after PYGO2 knockdown reduced colony 
formation efficiency. Also, colonies formed were smaller, indicating PYGO2 
affects anchorage-independent growth in EOC. In addition, subcutaneous 
implantation of these cells into SCID mice displayed smaller and slower 
tumourigenic growths, with a significant difference in tumour mass between 
PYGO2 knockdown and control mice 18 weeks post-implantation. Taken 
together, PYGO2 affects both anchorage-dependent and anchorage-
independent growths of EOC cells in vitro and in vivo, independent of β-
catenin/TCF status. In another study, BCL9L transcript expression was found 
to have increased two-fold in persistent tumour samples matched against 
primary tumour samples.442 Of note, persistent tumour samples displayed 
higher expression profile of stem-like markers including ALDH1A, CD44 and 
CD133, indicating the presence of ovarian cancer stem cells (CSC). This may 
suggest upregulated β-catenin/TCF transcriptional activity in ovarian CSCs. 
   Receptor-Interacting Protein Kinase 4 (RIPK4) is a serine/ threonine kinase 
interacting with protein kinase C delta (PRKCδ) that was previously reported 
to activate NFκB and JNK.443,444 RIPK4 overexpression in human embryonic 
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kidney 293T cells (HEK293T) upregulated WNT/β-catenin target genes 
transcript expression (CCND1, LEF1, JUN, c-MYC, TCF7), elevated 
TOPbrite TCF-luciferase reporter activity and increased the pool of cytosolic 
β-catenin, indicating that RIPK4 is an activator of WNT/β-catenin 
pathway.423 Conversely, siRNA-mediated knockdown of RIPK4 in Wnt3a-
treated A2780 and COV434 ovarian carcinoma cells abrogated TOPbrite 
TCF-luciferase activity and reduced cytosolic β-catenin accumulation. 
Furthermore, RIPK4 was shown to interact with and directly phosphorylate 
DVL2.423 RIPK4 was also shown to bind with LRP6 after Wnt3a stimulation, 
suggesting that upon Wnt3a ligand binding, LRP6 co-receptor recruits RIPK4 
to phosphorylate DVL2, which then associates with AXIN-GSK3 to disrupt 
formation of the β-catenin destruction complex, promoting cytosolic β-
catenin accumulation.423 Interestingly, human ovarian adenocarcinomas 
showed significantly higher RIPK4 transcript and protein expression 
accompanied by the presence of cytosolic β-catenin, as compared to normal 
ovarian tissue. This would suggest that RIPK4 mediates activation of WNT/β-
catenin signalling in ovarian cancer and thus RIPK4 may be a potential 
therapeutic target in treating ovarian cancer.423 
   WNTLESS (WLS) is a seven-transmembrane protein involved in the 
effective secretion of WNT ligands from the signalling cell to activate 
downstream WNT signalling.79-81 Immunohistochemical analysis of WLS 
expression in a panel of EOC and OSE patient specimens found WLS 
expression in 137/201 (68%) of EOC specimen but none of the OSE.424 Of 
note, a significant majority of OEA samples stained positively for WLS 
(19/23, 83%), supporting previous findings of aberrant WNT/β-catenin 
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signalling in OEAs (as described earlier). Also, significant majority of high-
grade serous ovarian carcinoma samples (89/116, 77%) express WLS, as 
compared to just 25% (5/20) of borderline and low-grade serous tumour 
samples, suggesting WNT as one of the drivers of EOC. Interestingly, 7/201 
(4%) of the EOC samples showed HER2 expression, all of which express 
WLS. Furthermore, 5/7 (71%) of the HER2-expressing tumours are of the 
serous histological subtype, showing a strong correlation between WLS and 
HER2 expression in serous ovarian carcinoma. This correlation may further 
suggest WLS/HER2 co-expression as a prognostic marker in serous ovarian 
carcinoma. 
 
WNT Ligands in EOC 
   In EOC, several reports have shown WNT ligands expression to be 
involved, mainly WNT2B,445,446 WNT5A363,418,447-450 and WNT7A.154,156,451 
WNT2B transcript expression was initially reported to be present in four 
ovarian carcinoma cell lines, namely: Caov-3, HEY, OVCAR-3 and SKOV-
3,445 while protein expression was reported in A2780 cells.446 siRNA-
mediated knockdown of WNT2B in A2780 cells (A2780:siWNT2B) reduced 
cell proliferation in colony formation assays.  Also, A2780:siWNT2B cells 
were less invasive in Matrigel. These findings suggest WNT2B to play a role 
in mediating ovarian cancer metastasis. Furthermore, A2780:siWNT2B cells 
showed increased chemosensitivity to paclitaxel in a dose-dependent manner 
(between 30-1000µM concentration), evident by an increase in propidium 
iodide positivity and the number of cells undergoing apoptosis (Annexin V 
positivity). Interestingly, A2780:siWNT2B cells showed elevated levels of 
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Caspase 9 (CASP9) expression, accompanied by reduced expression levels of 
anti-apoptotic BCL2 and BCL2L1, suggesting that the chemosensitivity 
phenotype observed is mediated by the CASP9/BCL2/BCL2L1 apoptotic 
machinery. 
   Microarray data showed WNT5A overexpression in EOC cultures as 
compared to OSE cells.363  In a separate microarray study, analysis showed 
upregulated WNT5A expression in A2780/C10B, an oxaliplatin-resistant 
derivative of parental A2780 human ovarian cancer cell line.418 Similarly, 
patient samples of melanoma cells gained resistance to the BRAF-inhibitor 
PLX4720 in a PI3K/AKT-dependent manner that is mediated by WNT5A.359 
Independently, an immunohistochemical study in primary patient samples 
showed WNT5A overexpression in the EOC samples. Furthermore, EOC 
patients overexpressing WNT5A showed poorer prognosis.447 Similar results 
were obtained from another independent study of similar design, whereby 
samples from EOC patients showed stronger WNT5A immunoreactivity and 
patients with WNT5A expression showed lower progression-free and overall 
survival.448 In addition, ectopic overexpression of WNT5A in SKOV-3 cells 
enhanced chemoresistance (increased IC50 values) to conventional 
chemotherapeutic reagents, including paclitaxel, oxaliplatin, 5-fluorouracil (5-
FU), epirubicin and etoposide. Further supporting this, WNT5A knockdown in 
SKOV-3 cells via RNA-interference (RNAi) enhanced chemosensitivity 
(decreased IC50 values) towards the aforementioned chemotherapeutic 
reagents,448 supporting a previous finding that WNT5A mediates 
chemoresistance.418  However, contradicting results were observed in another 
study.449 Immunohistochemical staining of WNT5A showed a majority of 
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EOC samples (81/130, 62%) to display lower WNT5A expression as 
compared to hOSE samples (13/31, 42%). Of note, a majority of the EOC 
samples are of the Type II high-grade serous classification. Also, lower 
WNT5A expression correlated to shorter overall survival. Both these findings 
contradict what was previously reported.363,447,448 It has been suggested that 
this discrepancy may be due to a difference in sample size (130449 vs. 38447 
and 63448). Also, it may be due to the difference in number of Types I and II 
tumour samples present in the other two studies. Of interest, WNT5A 
promoter regions in OVCAR-5 and PEO1 ovarian carcinoma cell lines were 
found to be hypermethylated. Treatment of PEO1 cells with a DNA 
demethylating agent 5-Aza-2’deoxyctiydine (5-Aza-C) increased WNT5A 
transcript and protein expression, demonstrating that WNT5A expression in 
EOC is epigenetically suppressed by gene promoter hypermethylation.449 
Furthermore, ectopic expression of WNT5A in the two cell lines inhibited both 
anchorage-dependent and anchorage-independent growths, with a marked 
reduction in the transcription expression levels of β-catenin target genes 
CCND1, c-MYC and FOSL1 (FOS-like antigen 1). Also, immunoblotting 
showed a reduction of soluble (thus active) β-catenin after WNT5A ectopic 
expression. These results indicate that WNT5A antagonizes the WNT/β-
catenin pathway. In addition, OVCAR-5 and PEO1s cells expressing WNT5A 
was shown to undergo cellular senescence, as shown by positive staining for 
the senescence marker SA-β-gal (senescence-associated beta-galactosidase). 
Furthermore, orthotopic injection of the WNT5A-expressing OVCAR-5 cells 
into the ovarian bursa of immunocompromised mice showed smaller tumour 
growths after 30 days as compared to the control. Further analysis showed 
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these WNT5A-expressing tumours to stain weakly for the proliferative 
marker Ki-67 but positively for SA-β-gal, indicating that WNT5A inhibited in 
vivo EOC tumourigenesis by promoting cellular senescence. In another 
immunohistochemical study involving a patient cohort of 623 samples (230 
benign controls, 86 borderline LMP tumours and 307 EOC samples), EOC 
samples displayed significantly higher WNT5A expression when compared 
against the benign controls and borderline tumours.450 Furthermore, 
reclassification of the EOC samples into either Type I or Type II groups all 
showed higher WNT5A expression against fallopian tubal epithelium, OSE 
and benign controls. However, no significant difference was observed when 
WNT5A expression status was measured against disease-free or relapse-free 
survival, suggesting that WNT5A is not a predictor of clinical outcome, as 
opposed to what was previously reported.448 In vitro treatment of an OSE cell 
line (HOSE6-3) with a human recombinant WNT5A stimulated WNT5A 
expression, followed by significant downregulated expression of β-catenin 
target genes CCND1, c-MYC and AXIN2. Concurrently, upregulation of non-
β-catenin pathway target genes was observed: Nuclear Factor of Activated T-
cells (NFAT), c-Jun N-terminal Kinase (JNK) and Protein Kinase C Alpha 
(PRKCA). This supports previous findings whereby WNT5A negatively 
regulates WNT/β-catenin pathway.449 Furthermore, WNT5A expression in 
HOSE6-3 drove cell migration and reduced cell-matrix adhesion towards 
collagen and fibronectin. In addition, E-cadherin (CDH1) protein expression 
was downregulated in WNT5A-expressing HOSE6-3 cells, accompanied by 
upregulation of the mesenchymal marker vimentin (VIM) and EMT drivers 
SNAIL1 (SNAI1) and SNAIL2 (SNAI2), suggesting that WNT5A can drive 
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EMT in EOC. siRNA-knockdown of WNT5A in OVCAR-3 serous ovarian 
adenocarcinoma cell line also reduced protein expression of VIM and SNAI2, 
suggesting an early stage of MET.450 However, transcript expression levels of 
the aforementioned target genes of both the WNT/β-catenin and the non-β-
catenin pathways showed no significant differences. It should be highlighted 
that parental OVCAR-3 displays a highly epithelial morphology and that 
using this cell line as a model for driving MET (knocking down WNT5A, a 
putative EMT driver) might prove difficult as the results here describes MET 
at a molecular rather than a cellular context.  
   Microarray analysis of tumour samples showed WNT7A expression to be 
higher in serous ovarian tumours compared to normal/benign samples.451 This 
is supported by transcript expression profiling of 300 tumours and normal 
ovarian samples, whereby WNT7A and WNT7B overexpression was observed 
in malignant samples when compared against normal ovarian specimens.156 
WNT3 and WNT4 were found to be downregulated while no significant 
difference was found between malignant and normal ovarian samples for the 
other WNT ligands. It should be highlighted here that expression of WNT5A 
in this study did not show any significant difference. In situ hybridization of 
the patient samples against WNT7A cRNA probes showed a significant 
majority of serous adenocarcinomas (65%) to have a higher expression 
profile. Also, SKOV-3.ip1 cells (derived from ascites of nude mice after 
intraperitoneal injection of parental SKOV-3 cells) showed elevated 
endogenous WNT7A, MMP7 and MMP9 expression as compared to the 
parental cells. WNT7A shRNA knockdown in SKOV-3.ip1 cells (SKOV-
3.ip1:shWNT7A) reduced expression of WNT/β-catenin target genes CCND1 
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and MMP7. Likewise, ectopic overexpression of WNT7A in parental SKOV-3 
cells showed upregulated expression of CCND1 and MMP7. Consistently, 
WNT7A knockdown in SKOV-3.ip1 cells reduced proliferation and WNT7A 
overexpression in SKOV-3 cells increased proliferative rates. Results from 
cell invasion assays show that overexpression of WNT7A in SKOV-3 cells 
increased cell invasiveness, whereas SKOV-3.ip1: shWNT7A cells displayed a 
less invasive phenotype. In agreement with this finding, 5 weeks post-
intraperitoneal injection of SKOV-3.ip1 cells into nude mice formed multiple 
tumour masses with implants around the peritoneal cavity, with some tumour 
masses invading into the bowels. In contrast, SKOV-3.ip1: shWNT7A cells 
developed one large tumour in the retroperitoneal space with less implants 
and no bowel-invasion observed. The vice versa effect was observed when 
WNT7A was overexpressed in SKOV-3 cells as compared to control 
conditions: larger tumour masses with evidence of tumour implants, bowel 
invasion and upregulated CCND1 expression. Furthermore, TOPflash 
luciferase assays show that WNT7A activates the WNT/β-catenin signalling 
pathway in this system. Interestingly, co-transfection of WNT7A and FZD5 
overexpressing constructs into both SKOV-3 and HEY cell lines containing 
TOPflash luciferase constructs further elevated luciferase activity as 
compared to just transfection of WNT7A construct alone, indicating that 
WNT7A is a ligand for FZD5 in EOCs. In addition, deletion of TCF/LEF 
binding sites on the promoter region of MMP7 in HEY ovarian papillary 
cystadenocarcinoma cells ectopically overexpressing WNT7A abrogated 
MMP7 luciferase reporter activity, indicating that WNT7A can target MMP7 
expression via the WNT/β-catenin-mediated pathway.156 Separately, 
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overexpression of WNT7A in OVCAR-3 ovarian adenocarcinoma cells 
enhanced cell migration and invasion properties in vitro (wound-healing assay 
and Matrigel invasion chamber assay).451 
   A follow-up study found WNT7A transcript expression to correlate with that 
of FGF1 in serous and clear cell carcinoma samples.154 Furthermore, 
correlation in protein expression levels was observed in SKOV-3.ip1 cells 
after WNT7A knockdown and in SKOV-3 cells after WNT7A overexpression. 
This correlation was also observed after these cells generated tumours in vivo. 
Analysis of the FGF1 promoter region identified 8 TCF/LEF consensus 
binding sites and ChIP assays of both SKOV-3.ip1 and WNT7A-
overexpressing A2780 cells showed enrichment of FGF1 in chromatin DNA 
pulled down by a TCF4 antibody. Furthermore, SKOV-3.ip1 cells carrying a 
dominant-negative TCF4 construct (dnTCF4) reduced FGF1 transcript 
expression levels. As expected, A2780 cells stably overexpressing either 
WNT7A (A2780:WNT7AOE) or FGF1 (A2780:FGF1OE) both displayed 
enhanced cell proliferation and adhesion to plastics. However, shRNA-
mediated knockdown of FGF1 in A2780 cells (A2780:WNT7OE/shFGF1) 
stably overexpressing WNT7A abrogated the enhancements observed. In 
addition, orthotopic tumours formed in vivo by A2780:WNT7AOE/shFGF1 
cells were significantly smaller than those of A2780:WNT7AOE and 
A2780:FGF1OE cells. Taken together, these results strongly support FGF1 as 
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Frizzled (FZD) Receptors and other co-receptors in EOC 
   Immunohistochemical analysis of patient specimens showed FZD1 
expression in a majority of both malignant and benign tumours (97% and 90% 
respectively), while significantly less in normal ovarian tissues (55%).447 In 
contrast, a cDNA array hybridization study found FZD3 expression to be 
downregulated in ovarian adenocarcinoma samples as compared to a benign 
adenoma sample.452 Furthermore, FZD3 expression was downregulated in 
advanced ovarian adenocarcinomas (more aggressive) as compared to highly 
differentiated ovarian adenocarcinomas (less aggressive).452 FZD4 loci 
hypermethylation in ovarian serous and ovarian endometrioid 
adenocarcinoma specimens showed association with disease progression 
(Hazard Ratio (HR): 2.5), higher risk of disease recurrence (HR: 0.8) and 
poorer overall survival (HR: 49.4), indicating that epigenetic silencing of 
FZD4 expression via promoter hypermethylation inversely correlated with 
prognosis and survival.453 However, it should be noted that Spearman’s 
correlation did not show statistical significance.453 FZD5 has been shown to 
be a receptor for WNT7A, whereby ectopic co-expression of WNT7A and 
FZD5 into both SKOV-3 and HEY ovarian carcinoma cell lines greatly 
increased TOPflash luciferase activity, as compared to just WNT7A 
overexpression alone.156 Comparative genomic hybridization (CGH) analysis 
of 46 sporadic and familial ovarian cancers showed one of the minimal region 
of interest commonly amplified to be within chromosome 2q32.1-34, which 
includes the loci for FZD5.362 However, immunohistochemical analysis of 
FZD5 expression showed no significant difference on prevalence between 
ovarian tumours and normal ovarian tissue specimens.447 Aside from the FZD 
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receptors, two co-receptors have also been implicated in ovarian cancer. In 
vitro culture of OVCA429 and OVCA433 ovarian carcinoma cells in type I 
collagen resulted in aggregation of integrin, inducing β-catenin/LEF/TCF 
transcriptional activity, including upregulated LRP6 expression.421 RYK is an 
atypical receptor tyrosine kinase demonstrated to act as a FZD co-receptor for 
the WNT/PCP pathway to mediate neurite outgrowths and axonal guidance 
during mammalian development.281,320-322,454 In normal OSE tissue, mRNA in 
situ hybridization (ISH) did not detect RYK expression. However, stromal 
regions surrounding benign and borderline tumours showed RYK expression 
while strong RYK expression was detected in the epithelium of malignant 
EOC tumours.455 In a follow-up study, EOC patient samples with high 
expression levels of RYK correlated with poorer outcome for overall 
survival.456 Interestingly, strong RYK expression in the endothelial and 
smooth muscle layer of blood vessels was also found to correlate with shorter 
overall survival, suggesting that RYK expression may potentially be used as a 
prognostic marker for EOC.456 Furthermore, in vitro functional studies 
showed overexpression of RYK in PEO4 ovarian carcinoma cells and 
NIH3T3 mouse fibroblast cells to enhance cell proliferation and anchorage 
independent growth in soft agar colony formation assays. Nude mice 
subcutaneously injected with NIH3T3 cells overexpressing RYK (with 
Matrigel) showed aggressive tumourigenic growths within 2 weeks, evident 
by peripheral skeletal muscle invasion and high mitotic index. In contrast, no 
tumourigenic growth was detected in control mice even after 6 months.457 
Taken together, RYK drives tumourigenesis and overexpression in EOC is 
indicative of poor prognosis. 
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Inhibitors of WNT Signalling (DKKs & SFRPs) in EOC 
   As described earlier, Dickkopf WNT signalling inhibitor 1 (DKK1), a 
member of the Dickkopf (DKK) secreted proteins, was shown to be a target 
gene of β-catenin in EOC417 and is involved in enhancing chemosensitivity.418 
Another study found transcript expression profile of DKK2 in primary EOC 
tumours to be significantly lower than that of benign tumours and normal 
ovarian specimens.458 DKK2 expression was also found to be very low in two 
EOC cell lines, SKOV-3 and ES-2. Similarly, immunohistochemical staining 
of DKK2 in tissue specimens showed EOC samples to display significantly 
reduced immunoreactivity compared to normal ovarian tissue and benign 
tumours. Methylation-specific PCR (MSP) analysis subsequently showed 
DKK2 promoter hypermethylation in SKOV-3, ES-2 EOC cells and 27/50 
(54%) of EOC samples. In contrast, DKK2 promoter hypermethylation was 
undetectable in all of the normal ovarian tissue and benign tumour samples. 
Exogenously overexpressed DKK2 in both SKOV-3 and ES-2 cells negatively 
regulates cell proliferation, migration and invasion. In agreement with the in 
vitro data, SKOV-3:DKK2OE cells formed significantly smaller tumours after 
subcutaneous injection into nude mice. Furthermore, treatment of SKOV-3 
and ES-2 cells with the demethylating agent 5-Aza-C showed similar effects 
to DKK2 exogenous overexpression: cell proliferation impairment in vitro 
and reduced tumourigenic potential in vivo. Interestingly SKOV-3:DKK2OE 
cells show downregulated  transcript expression for c-MYC and CCND1, 
target genes of β-catenin/TCF transcription, accompanied by downregulated 
protein levels for other β-catenin/TCF transcription targets FAK and MMP2, 
which may explain the invasion-impaired phenotype.  
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   Mean serum DKK3 expression was reported to be lower in 36 ovarian 
cancer samples (~26 pg/mL) as compared to that of 30 normal healthy 
controls (42 pg/mL).459 Also, a Japanese study reported that serum DKK3 
reduced slightly in late stage ovarian cancer when compared against the early 
stages,460 suggesting DKK3 to be a tumour suppressor in ovarian cancer. In 
another study, 35/56 (63%) EOC samples showed reduced DKK3 transcript 
expression when compared to that of normal ovarian tissue.461 Further 
immunohistochemical analysis of the 56 EOC samples showed 37 (66%) with 
either negative or weak membranous staining. In a recent study, DKK3 
protein expression was detected in 4 ovarian mucinous carcinoma cell lines 
(RMUG-S, RMUG-L, OMC and MCAS) and 1 ovarian clear cell carcinoma 
cell lines (RMG-1).462 siRNA-mediated knockdown of DKK3 in MCAS and 
RMG-1 cells increased cell proliferation, suggesting a tumour suppressor 
effect of DKK3. In addition, MCAS:siDKK3 cells showed reduced protein 
expression for pro-apoptotic factors, including CASP3, -8 and -9, BAX, 
FAS/CD95, JNK and p53 and increased anti-apoptotic BCL2 protein 
expression, which plays in a role in mitochondrial outer membrane 
permeabilization (MOMP). However, overexpression of DKK3 in MCAS 
cells did not show any changes in the protein expression levels of all the 
apoptotic factors, suggesting that only a basal level of DKK3 is required for 
inducing apoptosis. Taken together, these results show that DKK3 acts as a 
tumour suppressor by promoting apoptosis in mucinous ovarian cancer via the 
mitochondria and the FAS death receptor path.462 
   Secreted Frizzled Related Proteins (SFRPs) are secreted WNT antagonistic 
proteins bearing homology to the cysteine rich domain (CRD) of FZD 
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receptors, capable of binding to extracellular WNT ligands to prevent 
activation of cellular WNT signalling. In the human genome, five SFRPs have 
been identified, namely SFRP1, -2, -4, -5 and FRZB (Frizzled related protein, 
also known as SFRP3). In EOC, epigenetic alterations of SFRP1, -2, -4 and -5 
has been reported.463-470 MSP analysis of a panel of ovarian carcinoma cell 
lines representing all four major histological subtypes and a human OSE cell 
line found CpG island (CGI) DNA methylation in the SFRP1 promoter 
sequence of some cell lines but not in the HOSE cell line (summarized in 
Table 5).463  
Table 5: Summary of SFRP1 CpG Island (CGI) Methylation Status in Cells  
 lines of Ovarian Carcinomas and OSE 






ES-2 Clear Cell - ++ 
HTOA Serous - + 
JHOS-2 Serous - ++ 
KURAMOCHI Undifferentiated - +/- 
MCAS Mucinous + - 
OV-90 Serous +/- +/- 
RMG-I Clear Cell +/- - 
RMUG-L Mucinous + - 
RMUG-S Mucinous - + 
RTSG Poorly diff. + - 
TOV21G Clear Cell - ++ 
TOV112D Endometrioid - +/- 
TYK-nu Undifferentiated + - 
HOSE OSE - + 
 
Transcription expression profile supports the MSP analysis, whereby ovarian 
carcinoma cell lines with DNA hypermethylation to be devoid of SFRP1 
expression, and vice versa. Treatment of MCAS mucinous ovarian carcinoma 
cell line with 5-Aza-C demethylating agent showed reversal of SFRP1 CGI 
promoter methylation status, showing that SFRP1 may be epigenetically 
modulated in some EOC. Furthermore, MSP analysis of SFRP1 promoter CGI 
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status in 17 primary ovarian tumour specimens and seven endometrial cysts 
showed 2/17 (12%) tumour specimens with hypermethylation, while the only 
one endometrial cyst showed trace levels of methylation. Separately, another 
study found SFRP1 hypermethylation in 12/36 (33%) of ovarian clear cell 
adenocarcinoma samples.470 This further supports the notion of SFRP1 
regulation via epigenetic silencing in EOC.463 A subsequent epigenetic study 
on a larger cohort of ovarian cancer patient samples (126 malignant, 14 
borderline and 75 benign) found CGI hypermethylation to be significantly 
increased during malignant progression for SFRP1, -2 and -5.464 Furthermore, 
patient samples with SFRP1 hypermethylation showed higher relative risk 
towards recurrence and a worse prognosis, and SFRP1 methylation status 
showed significant concordance between a cohort of paired tissue/serum 
patient samples, potentiating SFRP1 hypermethylation as a prognostic 
marker.464 Taken together, these suggest the notion of prevailing aberrant 
WNT signalling as ovarian cancer progresses towards malignancy. 
Separately, SFRP2 was shown to inhibit WNT7A/FZD5-mediated β-
catenin/TCF transcriptional activity in SKOV-3 and HEY ovarian carcinoma 
cell lines, evident by significant reduction in TOPflash luciferase activity.156 
In another study, SFRP4 transcripts were differentially expressed among 
A2780 ovarian carcinoma cells and two chemoresistant-derivatives of the line 
(Adriamycin-resistant A2780-ADR and cisplatin-resistant A2780-Cis).465 
SFRP4 expression was also higher in an immortalized OSE (IOSE) line. 
Interestingly, immunohistochemical analysis of IOSE and parental A2780 
cells after cisplatin-treatment showed that a majority of cells that survived 
were negative for SFRP4 staining. Ectopic SFRP4 overexpression in A2780-
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ADR and A2780-Cis chemoresistant lines abolished cisplatin-
chemoresistance as compared to the controls. Conversely, siRNA-mediated 
knockdown of SFRP4 in A2780 parental cells showed elevated 
chemoresistance to cisplatin. Immunoblots showed an inverse correlation 
between SFRP4 and β-catenin protein expression levels,465 a trend observed 
from tissue microarray (TMA) immunohistochemical (IHC) analysis of 
primary mucinous465 and serous carcinomas.466 In another separate study, 
ascitic samples from two patients with progressive chemoresistance collected 
at later timepoints during treatment displayed reduced SFRP4 protein 
expression as compared to the earlier timepoint, accompanied by decreased 
GSK-3β and increased in active β-catenin expression.467 These results 
indicate that the WNT/β-catenin pathway mediates the chemoresistance effect 
induced by SFRP4. Furthermore, TMA-IHC analysis of 104 primary ovarian 
mucinous tumour samples showed significantly lower SFRP4 expression in 
mucinous adenocarcinomas as compared to the benign or borderline 
groups.465 Similarly, another TMA-IHC analysis involving 721 patient 
samples displayed significantly reduced SFRP4 expression in EOC compared 
to benign tumours.467 In addition, this trend was also observed in patient 
plasma samples using ELISA-based detection (Enzyme linked 
immunosorbent assay) of SFRP4. Of clinical relevance, patient samples 
lacking membrane SFRP4 expression was found to be associated with shorter 
overall survival.467 Taken together, these results indicate that SFRP4 
promotes chemosensitivity in EOC via the WNT/β-catenin pathway and that 
lost of SFRP4 is associated with disease progression towards malignancy and 
presents a worse prognosis.465-467 Separately, SFRP4 promoter 
	   75	  
hypermethylation in ovarian clear cell adenocarcinoma tissues is rare, with a 
prevalence of ~10% (5/48).470 In a follow-up study, introduction of SFRP4 to 
OVCAR-3 serous ovarian carcinoma cells with human recombinant SFRP4 
(rSFRP4) reduced β-catenin/TCF/LEF transcription activity, as validated by 
TOPflash luciferase reporter assays.468 Furthermore, SFRP4-treatment 
downregulated transcript levels of β-catenin target genes CCND1, c-MYC and 
AXIN2, but not of target genes of the β-catenin-independent (PCP and Ca2+) 
pathways: JNK, RHOA, RAC1 and PRKCA. Reintroduction of SFRP4 into 
OVCAR-3 cells impaired cell migration during wound healing assays, 
accompanied by increased integrin adhesion towards collagen and fibronectin. 
Furthermore, rSFRP4-treatment in OVCAR-3 cells increased protein 
expression of E-cadherin (CDH1), while decreasing expression of the 
mesenchymal intermediate filament vimentin (VIM) and the EMT-inducer 
TWIST1.468 Interestingly, a near opposite trend was observed in the presence 
of WNT5A,450 suggesting antagonism between WNT5A and SFRP4 in EOC.  
   SFRP5 hypermethylation prevalence during EOC disease progression was 
previously reported.464 Another study reported a higher prevalence of SFRP5 
CGI promoter hypermethylation in ovarian clear cell adenocarcinoma  (31/48, 
65%) than in ovarian serous adenocarcinoma (2/15, 13%) while normal 
ovarian epithelium do not display SFRP5 promoter hypermethylation.470 A 
follow-up study showed a functional EOC phenotype in SFRP5.469   MSP 
analysis of SFRP5 showed strong hypermethylation in SKOV-3 and A2780 
ovarian carcinoma cells, while OVCAR-3 and A2780/CP70 (cisplatin-
resistant derivative of A2780 cells) cells were partially hypermethylated. 
Interestingly, treatment of SKOV-3 and A2780 cells with 5-Aza-C (DNA 
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methyltransferase inhibitor) restored SFRP5 transcript expression, confirming 
epigenetic silencing via hypermethylation of SFRP5. This was also reported 
in several ovarian clear cell adenocarcinoma-derived cell lines (HAC-2, KK 
and RMG-II).470 Exogenous overexpression of SFRP5 in SKOV-3 and 
OVCAR-3 cells reduced colony formation in soft agar and invasion in 
Matrigel. Additionally, enhanced chemosensitivity towards chemotherapeutic 
agents cisplatin and taxol was observed.469 Furthermore, SFRP5 re-expression 
abrogated tumourigenesis in vivo SCID mouse models. Conversely, the vice-
versa trend was observed in A2780/CP70 cells after SFRP5 shRNA-mediated 
knockdown (A2780/CP70:shSFRP5).469 TOPflash luciferase reporter assays 
showed reduced luciferase activity in SKOV-3 cells after exogenous SFRP5 
overexpression. Furthermore, transcript expression of β-catenin target genes 
CCND1 and c-MYC were also downregulated after SFRP5 re-expression in 
SKOV-3 and OVCAR-3 cells. Similarly, A2780/CP70:shSFRP5 cells showed 
nuclear β-catenin immunoreactivity and increased CCND1 transcript 
expression. These would suggest that SFRP5 targets the β-catenin/TCF/LEF 
pathway. Of clinical relevance, majority of patients with SFRP5 
hypermethylation had poorer response to chemotherapy as compared to 
patients without SFRP5 methylation. Furthermore, ovarian clear cell 
adenocarcinoma patients with SFRP5 hypermethylation had shorter overall 
survival as compared to patients with unmethylated SFRP5.470 This would 
suggest that epigenetic silencing of SFPR5 enhances chemoresistance in 
EOC, resulting in poorer prognosis. 
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CHAPTER 1.4 
Hypothesis and Aim 
FZD7 transcript expression was previously reported to be up-regulated in 
SKOV-3 ovarian adenocarcinoma cells-derived spheroids.243 Furthermore, 
previous studies carried out on primary neuronal and mammary epithelial cells 
showed that spheroids derived from these cells are enriched for the stem-like/ 
progenitor populations, evident by the ability of these spheroid-derived cells to 
differentiate into different lineages of the respective systems.364,365 In addition, 
FZD7 was previously reported to regulate self-renewal of hESCs.366 Taken 
together, these results suggest FZD7 to play in role in regulating self-renewal 
of stem-like/ progenitor populations in ovarian cancer to promote metastasis. 
To this end, the role of FZD7 in mediating spheroid formation was studied and 
it was hypothesized that abrogation of FZD7 in ovarian cancer cells will 
inhibit spheroid formation by promoting anoikis, apoptotic cell death induced 
by dissociating of anchorage-dependent adherent cells. As such, the aim of 
this study was to generate stable knockdowns against FZD7 in ovarian cancer 
cell lines with high FZD7 expression and to evaluate if silencing of FZD7 
abrogates spheroid formation and induces anoikis. 	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CHAPTER 2 
Materials and Methods 
Cell Lines and cell culture 
CH1 cells were kind gifts from Dr. Noriomi Matsumura (Kyoto University, 
Japan) while OV17R and OAW28 cells were purchased from the European 
Collection of Cell Cultures (ECACC, Salisbury, UK). Dubelcco’s Modified 
Eagle’s Medium (DMEM) with high glucose (4500mg.L-1) and sodium 
pyruvate, DMEM/ Ham’s F-12 (1:1) media mix and fetal bovine serum (FBS) 
were from BioWest (Nuaillé, France). Supplements sodium pyruvate, bovine 
pancreatic insulin and hydrocortisone were all purchased from Sigma-Aldrich 
(St. Louis, MO). All cells were maintained in penicillin-streptomycin mix 
(Life Technologies-Gibco®, Grand Island, NY). See table below for culture 
conditions for each cell line. 
 Media FBS % (v/v) Additives 






CH1 DMEM 10 1mM - - 
OAWA28 DMEM 10 1mM 0.7 - 
OV17R DMEM/ 
Ham’s F-12 5 1mM 10 0.1 
 
RNA Isolation 
RNA from cell material were isolated using TRIzol® reagent (Ambion®-Life 
Technologies, Grand Island, NY) under a modified protocol from that of the 
user guide. Briefly, cells were lysed in TRIzol® at an approximate volume: 
growth surface area ratio of 800µL:10cm2 and mixed with 200µL of 
chloroform (amylene-stabilized, Sigma-Aldrich, St. Louis, MO) for every 
1mL of TRIzol® used. After phase separation by centrifugation (12,000x g for 
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15min at 4oC), the RNA-enriched aqueous phase was further purified using 
RNeasy mini spin columns (QIAGEN, Germantown, MD), with the on-
column DNase-treatment included prior to final elution. 
 
Quantitative Real Time Polymerase Chain Reaction (qPCR) 
An input of 500ng of total RNA of each individual samples were reverse 
transcribed into cDNA using pooled random hexamers and oligo-dT 
(Thymine) primers as according to user instructions of the RT2 First Strand kit 
(SABiosciences-QIAGEN, Germantown, MD). qPCR reactions were prepared 
using the 2x SYBR Green RT2 qPCR Master Mix (with ROX internal 
reference dye, SABiosciences-QIAGEN, Germantown, MD) with an input of 
~5ng cDNA and mixed to a final reaction volume of 25µL per well. The same 
protocol was used for the human WNT Signalling Pathway Plus PCR Array 
(SABiosciences-QIAGEN, Germantown, MD). All qPCR reactions were ran 
on the 7900HT Real Time PCR System (Applied Biosystems/ Life 
Technologies, Grand Island, NY) under a 40-cycle standard run. Raw 
threshold cycle (CT) values were determined with the SDS software (version 
2.3). To calculate fold change differences of gene transcript expression, the 
raw CT value of the gene of interest (GOI) was subtracted from the average CT 
value of the house keeping genes (HKG) used in the array, namely beta-actin 
(ACTB), beta 2 microglobulin (B2M), glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), hypoxanthine phosphoribosyltransferase 1 
(HPRT1) and ribosomal protein, large 13A (RPL13A). This subtracted value 
becomes the ΔCT, which is then compared between the control and the 
respective conditions to generate the ΔΔCT. Fold change is expressed as the 
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value from the negative exponent of ΔΔCT to the base of two (2-ΔΔCT). For 
calculation of percentage of transcript knockdown efficiency, the formula (1-
2-ΔΔCT) was used, with the overall value being expressed in percentage (%). 
 
Spheroid Formation and Anoikis Assay 
Ovarian carcinoma cell lines cultured on adherent plastic (Delta-treated 
surface, Thermo Scientific-Nunc, Grand Island, NY) were trypsin-dissociated 
(Nacalai Tesque, Kyoto, Japan) between 70-90% confluency and strained with 
a 40µm-porosity strainer (Greiner Bio-one, Frickenhausen, Germany) to 
acquire a suspension of single cells. Single-cells suspension were seeded onto 
neutrally charged and hydrophilic flat-bottomed 96-well ultra-low attachment 
surface (ULAS, Corning, Tewksbury, MA) at a density of 200 cells/ well and 
left in culture for a week to determine spheroid formation capabilities. ULAS 
coating prevents ionic interactions between cells and the surface, disrupting 
anchorage-dependent adhesion in the process, thereby allowing the evaluation 
of anchorage-independent growth capabilities. Protocol for anoikis assay is the 
same as that mentioned in the spheroid formation assay, with the exception 
that the entire cell suspension was harvested after various timepoints (between 
24-168hrs) for either Annexin V flow cytometry cell sorting or 
immunoblotting. 
 
Fluorescence-activated Cell Sorting (FACS) Flow Cytometry 
Briefly, adherent cells were trypsin-dissociated and re-suspended in FBS-
supplemented media. 1x105 cells were counted and washed twice with 1x PBS 
(phosphate-buffered saline). For suspension cultures, the entire cell suspension 
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was trypsin-dissociated (for dissociating spheroids) prior to resuspension, 
counting and PBS wash as before. PBS-washed cells were subsequently rinsed 
in 1x Annexin V Binding Buffer (AVBB) and stained in 100µL of AVBB-
based staining solution, which consists of pacific blue-conjugated Annexin V 
(Life Technologies-Molecular Probes®, Carlsbad, CA) at 5µL per 1x105 cells 
and propidium iodide (Sigma-Aldrich, St. Louis, MO) at 2µg.mL-1. Cells were 
incubated for 15 min at room temperature, washed once in AVBB before 
suspension in 1x PBS (200µL/ 1x 105 cells). Stained cells were strained 
through 70µm porosity cell strainer (Greiner Bio-one, Frickenhausen, 
Germany) prior to FACS analysis. FACS was performed on the LSRII flow 
cytometer (Becton-Dickinson™, San Jose, CA) and data analysed with the 
FACSDiva software (Becton-Dickinson™, San Jose, CA). 
 
shRNA and shRNAmiR-mediated Knockdown 
Ribonucleic acid interference (RNAi) via short hairpin RNA (shRNA) was 
used to generate stable clones of cells with the knockdown for the genes of 
interest. Lentiviral particle transduction was used to generate stable 
knockdowns for FZD7 and WLS. For FZD7, the MISSION® shRNA system 
(designed by The RNAi Consortium [TRC], Cambridge, MA; distributed by 
Sigma-Aldrich, St. Louis, MO) was used. The shFZD7 lentiviral plasmids 
were purchased from Sigma-Aldrich (St. Louis, MO). Briefly, each lentiviral 
plasmid vector (pLKO.1-Puro) contains various 21-base sense and antisense 
short hairpin sequence verified to target specific regions of FZD7 (see table 
below for sequence). The microRNA (miRNA) miR-155-based shWLS 
plasmids (pMSCV-Blst: shWLSmiR155) were kind gifts from Dr. YU Jia from 
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Prof. David VIRSHUP’s lab (Duke-NUS Graduate Medical School, 
Singapore). Briefly, two 21-base WLS coding sequence were separately cloned 
into the stem loop region of the miR155 precursor expression cassette, flanked 
by synthetic introns of the pSM155 miRNA vector.471 Of note, the mature 
miR155 sequence has been replaced by the WLS coding sequence, effectively 
eliminating any miR155-specific off-target effects. The advantage of this 
system is the utilization of the precursor sequence of miR155 into naturally 
processing the shWLSmiR155-cassette, thereby improving the knockdown 
efficiency. The entire shWLS-miRNA expression cassette was subsequently 
cloned into the pMSCV-Blst vector to allow Blasticidin-based antibiotic 
selection for stable clones. When selecting for stable clones, CH1 and OV17R 
cells were cultured in conditions as previously mentioned above, with the 
addition of either puromycin (Life Technologies-Gibco®, Carlsbad, CA) or 
blasticidin (Sigma-Aldrich, St. Louis, MO) for selection antibiotics at 
concentrations stated below: 
 Puromycin (µg.mL-1) Blasticidin (µg.mL-1) 
CH1 1.0 4.0 
OAW28 4.0 N.A. 
OV17R 4.0 20.0 
pLKO.1-puro: shFZD7 (sense strand in blue, anti-sense strand in red) 















2030 – 2050 3’UTR 
pMSCV-Blst: shWLSmiR155 
 Sequence From – To Region 
155-1 ACCAAGAAGCTGTGCATTGTT 0333 – 0353 Exon 01 
155-5 TGGACATTGCCTTCAAGCTAA 0649 – 0669 Exon 02 
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Selection antibiotics-resistant single colonies were individually picked after 
culture (~2 months) and expanded. Knockdown efficiency of individual clones 




Whole cell lysates were prepared using radio-immunoprecipitation assay 
(RIPA) buffer (Sigma-Aldrich, St. Louis, MO) supplemented with 
phosphatase inhibitor cocktail set II and protease inhibitor cocktail set I (EMD 
Millipore, Billerica, MA). Lysate supernatant were collected after 30min lysis 
on ice and centrifugation at 9000x g (10 min at 4oC). Bicinchoninic acid 
(BCA) protein assay kit (Thermo Scientific-Pierce™, Rockford, IL) was used 
to quantitate the lysates as per instructions stated on the user guide. Lysates 
were resolved on SDS-PAG (sodium dodecyl sulphate polyacrylamide) gel 
with varying polyacrylamide concentrations and transferred onto Immobilon®-
FL polyvinylidene difluoride (PVDF) membranes (EMD Millipore, Billerica, 
MA), before blocking with the Odyssey® blocking buffer (LI-COR, Lincoln, 
NE) for 1hr at room temperature. Membranes were subsequently stained with 
the primary antibodies of interest and incubated overnight at 4oC and washed 
vigorously in 1x TBST (tris-buffered saline supplemented with 0.1% (v/v) 
tween-20) thereafter. Membranes were then probed with IRDye® secondary 
antibodies for an hour at room temperature and washed with 1x TBST as 
before. Blots were analyzed on the Odyssey® CLx infrared imaging system 
(LI-COR, Lincoln, NE). 
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Immunofluorescence staining and Confocal Imaging 
Cells were cultured on glass coverslips (Marienfeld-Superior, Lauda-
Königshofen, Germany) and fixed in 4% paraformaldehyde (PFA, Electron 
Microscopy Sciences, Hatfield, PA) for 10min and permeabilized in 0.05% 
TRITON® X-100 (Sigma-Aldrich, St. Louis, MO). All reagents were prepared 
in 1x PBS and carried out room temperature unless specified. PFA-fixed cells 
were probed with respective primary antibodies of interest for 1hr and 
fluorescently labeled with Alexa Fluor® antibodies (Life Technologies-
Molecular Probes®, Carlsbad, CA) for 1hr. For visualization of F-actin 
filaments, cells were stained with tetramethylrhodamine B isothiocyanate 
(TRITC) conjugated-Phalloidin at 50µg.mL-1 for 30min (Sigma-Aldrich, St. 
Louis, MO). Cells were counterstained with VECTASHIELD® mounting 
medium with 4’,6-diamidino-2-phenylindole (DAPI, Vector-Laboratories, 
Burlingame, CA) and imaged using the Nikon A1+ confocal microscope 
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CHAPTER 3 
Results 
Stem-A molecular subtype teratocarcinoma and ovarian carcinoma cell lines 
generally have higher FZD7 transcript expression 
Based on the FZD7 transcript expression profiling of the library of ovarian 
carcinoma cell lines available from our collection, it was observed that cell 
lines with the highest FZD7 expression fall into the Stem-A molecular 
subtype, including the teratocarcinoma cell lines PA1 and CH1, and several 
ovarian carcinoma cell lines COV318, OV17R, OVCAR-3, OAW28, JHOS-4, 
and TOV-112D all having over 2-fold change expression over PEO1 (Figure 
1A), supporting earlier reports of FZD7’s role in the maintenance of the 
stemness phenotype. However, it should also be noted that some Stem-A-
classified ovarian carcinoma cell lines (OVK18, IGROV-1 and OAW42) 
displayed very low FZD7 transcript expression. Furthermore, when FZD7 
transcript expression profile is grouped between Stem-A and non Stem-A cell 
lines, the Stem-A group shows significantly (p=0.0011) higher expression as 
compared against the non Stem-A group (Figure 1B).  
 
Knockdown of FZD7 in spheroid-forming ovarian cancer cells disrupts 
spheroid-formation 
Previously, FZD7 transcript expression was shown to be up-regulated in 
spheroids formed by SKOV-3 ovarian adenocarcinoma cells,243 suggesting 
that FZD7 (presumably through the WNT signalling pathway) plays a role in 
mediating spheroid formation. To test this further, a human teratocarcinoma 
cell line of ovarian origin (CH1) was chosen for subsequent studies for two 
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Figure 1A: FZD7 transcript expression profile from a library of ovarian carcinoma 
cell lines. ΔΔCT values were obtained by normalizing the expression profile against 
that of PEO1, an epithelial ovarian adenocarcinoma cell line472 (marked in blue). 
Error bars represent the standard error (SE) of experimental duplicates. 
Teratocarcinoma cell lines are shaded in red, Stem-A molecular subtype cells are 
shaded in orange31 while immortalized ovarian surface epithelium (IOSE) cell lines 
are shaded in yellow. 
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Figure 1B: Box plot comparing the relative FZD7 transcript expression fold change 
between Stem-A and non Stem-A cell lines. Unpaired T-test (two-tailed, unequal 
variance) was performed to determine statistical significance. Double asterisks 
indicate p–value <0.005. 
 
reasons: i) CH1 has one of the highest FZD7 transcript expression levels in 
our library of ovarian cancer cell lines, and ii) CH1 cells grow spheroids at a 
relatively fast rate due to the short doubling time and thus provide a model 
whereby the role of FZD7 in mediating spheroid formation can be quickly 
validated. In this study, FZD7 transcript expression from CH1-derived 
spheroids showed ~1.6 fold increase relative to CH1 cells cultured in adherent 
conditions (Figure 2A), supporting initial observations made in SKOV-3 
derived spheroids.243 As such, lentiviral-transduction based techniques were 
used to introduce constructs carrying short hairpin RNA (shRNA) sequences 
into parental CH1 cells and single colonies were validated after puromycin-
selection. Of the various shFZD7 constructs used, two showed the best 
knockdown of ~51% (shFZD7: 778-6, termed CH1:778-6 from here on) and 
FZD7 Transcript Expression between Stem-A and non Stem-A    
































	   88	  
 
 
~73% (shFZD7: 2030-2, termed CH1:2030-2 from here on, Figure 2B) 
respectively. As a control, a construct of the same backbone targeting the 
luciferase gene (shLuc, termed CH1:shLuc) was used.  
 
	   	  	   	  
	   	  	   	  	   	  	  
	   	  	   	  	   	  	  	  	  
	   	  	  	   	  
Figure 2: Characterization of CH1 shFZD7 cells after lentiviral transduction. A) 
FZD7 expression is upregulated in CH1 and SKOV-3-derived spheroids. B) Bar 
chart depicting the knockdown levels of two CH1 shFZD7 clones (778-6 and 
2030-2) relative to the luciferase control. C) Phase contrast images of CH1 
shFZD7 cells during adherent culture at 10x magnification and D) suspension 
culture at 20x magnification. E) Reduced cell doubling rates and F) abrogation 
of spheroid formation of CH1 cells after shFZD7 knockdown. Single asterisks 
(*) represent statistical significance with p-value <0.05 while double asterisks 
(**) statistical significance with p-value <0.005. Student’s T-test were 
performed (two-tailed, equal variance). 	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Following expansion of these stable clones, CH1:2030-2 cells were observed 
to display a more compact epithelial-like morphology as compared to the 
mesenchymal morphology of CH1:shLuc luciferase control cells (Figure 2C). 
 
In addition, CH1:2030-2 cells showed reduced proliferation (Figure 2E). 
However, these differences were not observed in CH1:778-6 FZD7 
knockdown cells. CH1:shLuc, CH1:778-6 and CH1:2030-2 cells were 
subsequently cultured in suspension for 1 week to test for spheroid formation 
efficiency (Figures 2D & F). After which, CH1:shLuc cells on average 
displayed a spheroid formation efficiency of 300 cells/spheroid (1 spheroid-
forming cell for every 300 viable cells). In contrast, after FZD7 knockdown, 
both CH1:778-6 and CH1:2030-2 cells has a spheroid formation efficiency of 
~2400 cells/spheroid, clearly indicating that FZD7 plays in role in mediating 
spheroid formation in CH1 cells. 
 
FZD7 knockdown in CH1 cells promotes anoikis via the extrinsic pathway 
Anoikis is defined as a form of apoptotic cell death induced by abrogating cell-
substrate adhesion. To investigate whether the suppression of spheroid 
formation in CH1 shFZD7 was caused by anoikis, annexin V was used to 
detect the presence of phosphatidylserine (PS) phospholipid in CH1 shFZD7 
cells that were cultured in suspension. In normal viable cells, PS is located in 
the cytoplasmic cell membrane. However, during early and intermediate 
stages of apoptosis, PS is translocated to the outer surface of the plasma 
membrane, which can be readily detected by the Ca2+-dependent annexin V 
phospholipid-binding protein.473-475 Using fluorescently-conjugated annexin 
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Figure 3B: Summary of the anoikis assay of CH1 shFZD7 cells over the indicated 
timepoints. Student’s T-test (two-tailed, equal variance) was performed to determine 
statistical significance, with single asterisk (*) representing statistical significance (p-
value < 0.05). 
 
 
V, FACS via flow cytometry can be used to quantitate the population of 
annexin V-positive cells.474 In this study, CH1 shFZD7 cells were cultured in 
suspension as before and cells at the various time-points (48hrs/2days, 
96hrs/4days and 168hrs/1week) were harvested and stained for annexin V-
conjugated with the Pacific Blue fluorescent probes and analyzed via FACS  






























CH1 shFZD7 Anoikis (Annexin V) 
CH1:shLuc CH1:778-6 CH1: 2030-2 
* 
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As shown, annexin V-positive cells increased in suspension culture over time. 
In addition, pro-apoptotic-related markers were investigated in whole cell 
lysates harvested from the same experiments, including: Caspase-3 (CASP3) 
and Poly (ADP-Ribose) Polymerase (PARP) and the anti-apoptotic Myeloid 
Cell Leukemia 1 (MCL-1) (Figure 3C). In this study, cleaved CASP3 was 
detected early in CH1 suspension cultures (48hrs) for both shLuc control and 
shFZD7 knockdowns, corresponding to the cleavage of PARP, further 
increasing in intensity at the 96hr time-point. However, cleavage activity of 
CASP3 and PARP were observed to be higher after FZD7 knockdown. Of 
note, the band intensity of the cleaved CASP3 bands (p19 and p17) were both 
higher after shFZD7-mediated knockdown in suspension culture. The 
activation of CASP3-PARP cascade indicates that FZD7 promotes anoikis in 
CH1 cells via the extrinsic pathway. Furthermore, Caspase-9 (CASP9) was 
also probed for but did not show any differences, indicating that FZD7 did not 
mediate the intrinsic pathway of apoptosis (data not shown). Interestingly, 
down-regulation of anti-apoptotic Mcl-1 in CH1 shFZD7 cells (in both 
adherent/2D and suspension/3D cultures) suggests that FZD7 mediates the 
extrinsic apoptotic pathway through regulation of Mcl-1. As Mcl-1 is part of 
the anti-apoptotic Bcl-2 family, Bcl-2 was also probed for but was not 
detected (data not shown).	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FZD7 knockdown in OV17R ovarian adenocarcinoma cells promoted anoikis 
As the results presented thus far are based on CH1, a teratocarcinoma cell line 
of ovarian origin, these data were validated in an ovarian cancer cell line 
instead. Using the same shFZD7 constructs used for CH1 cells (shFZD7:778 
and shFZD7:2030), stable knockdowns of FZD7 were established in OV17R, 
a stem-A classified ovarian adenocarcinoma cell line with high FZD7 
transcript expression (Figure 1A). From the stable clones established, three 
were selected, one from the shFZD7:778 construct and two clones from the 
shFZD7:2030 construct (2030-1/clone 1 and 2030-3/clone 3), with transcript  
	  
	   	  	   	  	   	  	   	  
Figure 4A: FZD7 knockdown in OV17R cells. Bar chart illustrating the relative FZD7 
transcript expression levels after shFZD7-mediated knockdown. Student’s T-test (two-
tailed, equal variance) was used to determine statistical significance. Single asterisk (*) 
indicates statistical significance with p-value <0.05 while double asterisks (**) indicate 
statistical significance with p-value <0.005. Numbers below asterisks represent the 
average FZD7 transcript expression remaining after shFZD7 knockdown, relative to the 
shLuc control. Phase contrast images below show the morphology of OV17R cells after 
FZD7 knockdown. Images were captured at 10x magnification. 
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knockdown efficiency between 90-95% (Figure 4A). Two clones from the 
shFZD7:2030 construct were selected as both clones show different 
morphologies (Figure 4A, phase contrast images). Next, OV17R shFZD7 cells 
were cultured in suspension conditions identical to that of CH1 shFZD7 cells 
	  	  
 
Figure 4B: FACS analysis of the anoikis assay of OV17R cells after FZD7 knockdown 
(OV17R shFZD7). 
B i) Histograms of Annexin V-positive cells derived from the respective OV17R cells in 
adherent (2D) cultures over the three timepoints (48, 96 and 168 hrs). B ii) Histograms 
of Annexin V-positive cells derived from the respective OV17R cells in non-adherent / 
suspension (3D) cultures over the three timepoints (48, 96 and 168 hrs) ran in parallel 
with those described in (B i) 	  
B i) 
B ii) 
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Figure 4C: Summary of the anoikis assay of OV17R shFZD7 cells over the indicated 
timepoints. Student’s T-test (two-tailed, equal variance) was performed to determine 
statistical significance, with single asterisk (*) representing statistical significance (p-
value < 0.05). 
and Annexin V-positive cells were quantitated via FACS flow cytometry 
analysis as before (Figure 4B/C). Based on the FACS analysis carried out, 
OV17R:778 and OV17R:2030-1 cells showed significant increment of 
annexin V-positive cells after 96 and 168 hours respectively when in 
suspension culture (OV17R:77896hrs p-value= 0.040; OV17R:778168hrs p-
value= 0.017; OV17R:2030-1168hrs p-value= 0.050). However, immunoblotting 
of lysates harvested after 48 and 96 hours of suspension culture did not show 
the similar trend as compared to that of CH1 shFZD7 cells (Figure 4D), with 
only a slight increment of the cleaved-PARP band (89kD) observed at 48hrs 
of OV17R:2030-1 and that total Mcl-1 expression was downregulated in 
OV17R:2030-1 cells after 96hrs suspension culture. Cleaved CASP3 antibody 
detected only the 17kD cleaved band but not the 19kD band. This may 
indicate that the anoikis induced by FZD7 in OV17R cells could possibly 

































OV17R shFZD7 Anoikis (Annexin V) 
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Knockdown of FZD7 induces colony compaction and induced cytoskeletal 
reorganization in both CH1 and OV17R cells 
 
As the WNT/PCP-pathway is known to induce cytoskeletal reorganization and 
morphological transformations, it would seem plausible that the compaction of 
colonies formed in CH1 and OV17R shFZD7 cells may be due to the PCP-
pathway. To this end, confocal imaging was used to observe the distribution of 
actin filaments via phalloidin staining of F-actin in CH1 and OV17R cells 
after FZD7 knockdown (Figure 5A).  
In CH1 shFZD7 cells, colonies formed appeared more compact in clone 
CH1:2030-2, as noted previously. Of interest, Z-stacked images revealed 
CH1:shLuc control cells to display a denser F-actin network as compared to 
CH1:2030-2 cells (sidebar of Figure 5A II). However, there was no observable 
difference seen between CH1:shLuc control and CH1:778 cells. 
In OV17R shFZD7 cells, the effect of cytoskeletal reorganization was more 
visible, with a drastic change in F-actin distribution observed in OV17R:2030-
1 and 3 clones. One striking feature observed was a seemingly random layout 
of F-actin after FZD7 knockdown, as compared to a more orderly distribution 
in OV17R:shLuc control cells, whereby F-actin was observed to be mainly 
distributed around the periphery of each cell. Furthermore, there was a clear 
demarcation between F-actin and cell-cell junctions (represented by β-catenin, 
a marker of adherent junctions) in control cells, whereas β-catenin staining co-
localized with F-actin in OV17R shFZD7 cells, reinforcing the observation 
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A I)	  	  	  	  	  	  	  F-actin                 β-catenin                   DAPI                   Overlay 
	  	  	  	  	  	   	  
	  	  	  	  	  	   	  
	  	  	  	  	  	   	  
 
A II) 
                           CH1:shLuc                                        CH1:2030-2 
          
Figure 5A: Confocal images of CH1 shFZD7 cells stained for F-actin (red), β-
catenin (green) and DAPI nuclear stain (blue). AI) Images of CH1:shLuc and 
CH1 shFZD7 cells. A II) Enlarged Z-stacked images of CH1:shLuc and 
CH1:2030-2 cells stained against phalloidin (F-actin) showing greater detail on 
the distribution of F-actin. Notice the side bar indicating the stacked y-axis 
view, displaying the overall thickness of the cells. Of interest, CH1:shLuc cells 
show more depth in F-actin, as noted by the change in thickness of F-actin 
distribution and less intense phalloidin staining after FZD7 knockdown. All 
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B I) 
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B II) 
       OV17R:shLuc                   OV17R:2030-1                  OV17R:2030-3 
 
 
Figure 5B: Confocal images of OV17R shFZD7 cells stained for Phalloidin (F-
actin, red), β-catenin (green) and DAPI nuclear stain (blue). Notice the 
distribution of F-actin and compaction of nuclear distance after FZD7 
knockdown. B II) Enlarged Z-stacked images of OV17R:shLuc and OV17R:2030-
1 and -3 cells stained against phalloidin (F-actin) showing greater detail on the 
distribution of F-actin. Notice the side bar indicating the stacked y-axis view, 
displaying the overall thickness of the cells. In contrast to what was seen in CH1 
shFZD7 cells, OV17R shFZD7 cells show more depth in F-actin, as noted by the 
change in thickness of F-actin distribution and less intense phalloidin staining 
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Knockdown of FZD7 abrogated Phosphorylation of DVL2/3 proteins 
 
Dishevelled proteins have been previously reported to mediate the PCP-
pathway (refer to section 1.2 of Introduction). Furthermore, FZD10 was 
previously reported to activate the PCP-pathway by regulating Dvl2/3 
phosphorylation in synovial sarcoma.253 As such, it would be interesting to see 
if FZD7 knockdown has any effect on the PCP-pathway through Dvl2/3 
phosphorylation. Immunoblots from total cell lysates of CH1 shFZD7 and 
OV17R shFZD7 cells probed against Dvl2 and Dvl3 antibodies showed 
Dvl2/3 dephosphorylation in OV17R shFZD7 cells but not in CH1 shFZD7 
cells. In particular, OV17R:778 cells expressed much lower total Dvl2/3 
proteins, evident by the less intense bands observed (Figure 6). As such, these 
results indicate FZD7 to have a role in the phosphorylation of Dvl2/3 proteins 










Dvl2 	  	  	  	  	  	  	  	  	  
Dvl3 	  	  	  	  
Figure 6: Immunoblots of CH1 shFZD7 and OV17R shFZD7 cells probed 
against Dvl2 (95/90kD) and Dvl3 (93/88kD) proteins. The top bands (green) of 
each blot represents the phosphorylated form while the lower green band shows 
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Cyclin D2 (CCND2) is up-regulated in OV17R shFZD7 cells 
To better understand the WNT-related genes regulated by FZD7 in OV17R 
cells, a commercially available qPCR array on human WNT signalling 
pathway was used to analyse the transcript expression profile of 84 WNT 
pathway related genes between OV17R shLuc control and OV17R shFZD7 
cells. cDNA reverse transcribed from each of the conditions (control and 3 
knockdown clones) were ran on the qPCR array in triplicates, and compared 
with the transcript expression profile of the shLuc control. Based on the 
selection criteria that all three of the shFZD7 clones must show statistical 
significance (Student’s T-test: two tailed, equal variance) for the particular 
genes analyzed, two genes were found to pass this criteria, namely Cyclin D2 
(CCND2) and WNT5B. Both genes were up-regulated, with an average fold 
change of 1664 for CCND2 (p-value range: 0.005-0.02) and 8.1 for WNT5B 
(p-value range: 0.01-0.04). Immunoblot of the respective OV17R shFZD7 
total cell lysates were probed against a CCND2 antibody and does indeed 
show CCND2 up-regulated expression in all three of the OV17R shFZD7 
clones (Figure 7). Interestingly, OV17R exogenously expressing a FZD7 
cDNA construct also shows a slight up-regulation in CCND2. The same 
CCND2 antibody was also probed against CH1 shFZD7 total cell lysates. Of 
the four clones probed against, only one showed a slight increment of CCND2 
expression (CH1:1735-6), while a very faint band from the other three clones 
was observed, showing a very slight increment relative to the shLuc control. 
However, the increment of CCND2 expression in CH1 shFZD7 cells is almost 
negligible compared to what was observed in OV17R shFZD7 cells. 
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WLS, a WNT-transporter molecule is up-regulated in suspension cultures of 
ovarian teratocarcinoma and cancer cells 	  
In order to validate the shFZD7 data, it was sought to target another WNT-
related component to determine if the same pro-anoikis phenotype could be 
observed. WLS was eventually chosen as a target to disrupt. WLS is a seven-
transmembrane molecule responsible for transporting newly synthesized WNT 
ligands from the rough ER to the cell surface for secretion (refer to section 1.2 
of ‘Introduction). As such, by targeting WLS to inhibit WNT secretion, 
thereby ‘starving’ the cells from WNT ligands to inhibit WNT signalling, 
similar in effect to the disruption of the receptor (FZD7) level. In an initial 
screen for WLS expression, several cell lines of human ovarian origin that 
readily form spheroids (PA1, CH1 and the HEY-series: HEY, HEY A8 and 
	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
 
Figure 7: Immunoblot of OV17R and CH1 shFZD7 total cell lysates probed 

























































































	   104	  
HEY C2) were screened for WLS expression. Interestingly, spheroids formed 
from these cells when cultured in suspension showed up-regulated WLS 
expression relative to their respective adherent cultures (Figure 8A). This 
novel finding would suggest that WNT signalling activity may be elevated in 
suspension or spheroid cultures. 
 
WLS knockdown in PA1 cells reduced rate of cell growth 
Two shWLS constructs containing precursor elements of microRNA-155 
(miR-155) within the backbone vector were used to generate stable 
knockdowns of WLS in PA1, CH1 and OV17R cells. Essentially, the 
encoding of an artificial intronic miR-155 sequence flanking the shWLS 
sequence improves knockdown efficiency by allowing miR-155 to lead the 
shWLS sequence to target the WLS mRNA for degradation. After lentiviral 
transduction of viral particles carrying the respective shWLSmiR-155 constructs, 
stable clones were selected and knockdown validated. Transcript expression 
profiling shows knockdown efficiency between 75-80% relative to the empty 
vector controls (Figure 8B) and immunoblots of total cell lysates probed 
against a WLS mouse monoclonal antibody (mAb) showed reduced protein 
levels (Figure 8C), consistent with the level of transcripts detected. As an 
initial characterization, the cell growth rates were determined over a 72hrs 
period and PA1 cells carrying the shWLSmiR-155-5 construct (PA1:shWLS-5)  
showed significant reduction in growth rates (Figure 8D). 
 
 















Figure 8: A) Immunoblot of various human cell lines of ovarian origin cultured in 
adherent (2D) or suspension (3D) conditions and probed against WLS (YJ5) mAb 
(between 40-50kD). β-tubulin was used as the loading control (51kD). B) Transcript 
expression of WLS after shWLSmiR-155 mediated knockdown for both CH1 and PA1 
cells. C) Immunoblot of total cell lysates of CH1 and PA1 cells after shWLSmiR-155-
mediated WLS knockdown. Total cell lysates were probed against the WLS (YJ5) 
mAb. GAPDH (37kD, red) was used as a loading control. D) Characterization of 
cell growth rates of CH1 and PA1 cells after WLS-knockdown. Cells were seeded 
overnight and manually counted 24hrs post-seeding and taken as T0. Cells were 
trypsin-dissociated and counted as before after another 72hrs of culture. Bar chart 
represents the average rate of increment (T72/T0) of experimental triplicates and 
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PA1 parental and PA1 empty vector control cells (PA1:EV) showed ~20x 
increment in cell numbers over the 72hrs period, whereas PA1:shWLS-5 cells 
only increased by ~6x (p-value=0.03). Although PA1:shWLS-1 cells showed 
reduced growth rates as well (11x increment), no statistical significance was 
found. CH1 cells stably expressing the shWLSmiR-155-5 construct (CH1:shWLS-
5) also showed reduced cell growth rates (10.5x increment as compared to 
~13x increment of parental and empty vector control cells). However, 
statistical significance was not achieved. 
 
Inhibition of WLS slowed down rate of spheroid formation in CH1 cells 
The ability for spheroid formation after shWLSmiR-155-mediated knockdown 
was tested in CH1 cells. By the end of the first week, CH1:EV cells formed 
spheroids, averaging 263 ±61µm in diameter (Figure 9A/B). CH1:shWLSmiR-
155 cells formed spheroid-like aggregates averaging 101 ±31µm in diameter. 
However, after a two-week culture period, CH1:shWLSmiR-155 cells formed 
spheroids similar in size to that of CH1:EV spheroids formed during the first 
week, averaging 286 ±35µm in diameter. CH1:EV spheroids continued 
growing during the second week, averaging diamaters of 444 ±6µm. 
 











B)                    
 
Figure 9: Effects of WLS knockdown on spheroid formation in CH1. A) Phase 
contrast images of spheroids formed by CH1:EV and CH1:shWLS-1 cells after 1 
week (top panel) and two weeks (lower panel). Images taken at 10x 
magnification. B) Bar charts summarizing the average diameters of spheroids 
formed over the two timepoints after shWLS-mediated knockdown in CH1. 
Double asterisks represent statistical significance with p-value <0.005 
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shWLSmiR-155-mediated Knockdown did not significantly induce anoikis 
Following the initial characterization, PA1:shWLSmiR-155 cells was cultured in 
suspension to test for anoikis (Figure 10A). The general finding was that PA1 
cells underwent anoikis over a period of 96hrs. However, no significant 
difference was obeserved between PA1:shWLS-1/5 and PA1:EV control cells. 
Similarly, OV17R shWLSmiR-155 cells also did not show statistically significant 
increment in  annexin V-positivity, even though OV17R:shWLS-5 cells 
showed relatively higher percentage of annexin V-positivity (Figure 10B). As 
such, no definitive conlusion could be made from this set of data. 
 
                   
                   
Figure 10: Summary of the anoikis assay of CH1 and OV17R shWLSmiR-155 cells over 































PA1 shWLSmiR-155 Anoikis Assay (Annexin V) 


































OV17R shWLSmiR-155 Anoikis Assay (Annexin V) 
OV17R:EV OV17R:shWLS-1 OV17R:shWLS-5 
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CHAPTER 4 
Discussion 
   One of the ways in which ovarian cancer cells metastasize is through the 
shedding from the primary tumour site into the patient ascites, eventually 
forming secondary tumourigenic growths along the mesothelial lining of the 
peritoneal cavity. As such, a better understanding of the mechanisms involved 
in mediating this process is of great importance towards management of 
disease progression. Essentially, ovarian cancer cells that have shed must 
possess resistance towards the anoikis process: programmed cell death of 
anchorage-dependent cells when ‘displaced’ in a non-anchored environment. 
 
   Previously, spheroids (three-dimensional spherical aggregates) formed in 
vitro by SKOV-3 ovarian adenocarcinoma cells were shown to express 
elevated transcript levels of the WNT receptor FZD7, indicating the 
involvement of WNT signalling pathway.243 In this study, FZD7 was shown to 
mediate anoikis-resistance, whereby stable knockdown of FZD7 via RNA-
silencing techniques promoted anoikis in both CH1 ovarian teratocarcinoma 
and OV17R ovarian adenocarcinoma cells, resulting in the abrogation of 
spheroid formation in CH1 cells. Though this has not been reported in ovarian 
cancer, a similar finding has been reported in Wilm’s tumour cells,384 whereby 
anti-FZD7 antibody treatment in vitro induced cell death within the FZD7+ 
population of Wilm’s tumour cells, which are the stem-like/ progenitor pool of 
cells with spheroids-forming potential. As such, their study indicates that 
FZD7 is a potential therapeutic target used to eliminate the stem-like pool of 
Wilm’s tumour cells marked by the expression of FZD7. The current study 
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described in this manuscript supports the notion of FZD7 as a therapeutic 
target in ovarian cancer, whereby CH1 shFZD7 cells cultured in suspension 
display increased levels of cleaved-CASP3 and PARP activity, which is 
known to be part of the extrinsic pathway of the apoptotic mechanism. In 
addition, Mcl-1, a Bcl-2 family anti-apoptotic/ pro-survival gene was down-
regulated after FZD7 knockdown, further reinforcing the finding that CH1 
shFZD7 cells in suspension display higher proportion of annexin V-positivity, 
indicative of apoptotic activity/ anoikis.  
 
    Activation of WNT signalling has been reported to inhibit apoptosis, 
whereby the induction of WNT activity via Wnt3a-conditioned media rescued 
NIH3T3 cells from undergoing apoptosis in serum-starved conditions.476 
Furthermore, apoptosis-resistance derivatives of parental prostate cells showed 
enhanced TCF/LEF promoter activity, accompanied by elevated levels of 
nuclear and cytoplasmic β-catenin.477 Conversely, antisense β-catenin 
treatment of mouse embryonic liver explant cultures increased apoptosis, as 
evaluated by TUNEL-staining,478 while the inhibition of β-catenin-mediated 
Wnt activity via either Wnt1 mAb treatment or siRNA-silencing induced 
apoptosis in both rodent and cancer cells.99,479 In addition, overexpression of 
the WNT antagonist DKK1 has also been reported to promote apoptosis.480-482 
 
   Caspase3 (CASP3) is a cysteine aspartase that acts as an executor caspase 
during the induction of apoptosis. It exists as a 32kD zymogen that is activated 
by a two-stage mechanism, whereby it is first cleaved into a 19/12kD active 
intermediate (p19/p12) at Asp175 by other initiator caspases. Two p19/p12 
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intermediates form a heteromeric complex and undergoes autocatalytic 
cleavage at Asp28, resulting in the final p17 form.483 Interestingly, it has been 
shown that the p19 form can exist in the presence of cytochrome c (CYCS),484 
which is released during loss of mitochondrial outer membrane 
permeabilization (MOMP, reviewed in Tait and Green, 2013).485 While basal 
CASP3 activity was detected in the adherent/2D cultures of CH1 cells 
regardless of FZD7 levels, the suspension/3D cultures do however show more 
cleaved-CASP3 after shFZD7-mediated knockdown (evident by the more 
intense p19 and p17 bands relative to the control), which would support the 
role of FZD7 in mediating in anoikis. While the presence of the p19 form after 
shFZD7-mediated knockdown in CH1 cells during suspension culture 
conditions would seem to suggest that the anoikis undergone is of intrinsic 
nature, it should be highlighted that duration of MOMP is usually within the 
order of minutes, which would argue against the timepoints (48-168hrs) when 
the p19 bands were detected. Furthermore, CASP9 activity (initiator caspase 
responsible for activating CASP3 in the intrinsic pathway) was not detected in 
this anoikis assay. Interestingly, β-catenin has been reported to be cleaved by 
CASP3 in vitro during anoikis in mammary epithelial cells,486 indicating an 
inhibitory role of CASP3 on β-catenin-mediated WNT signalling. 
Furthermore, RNA-inhibition of β-catenin (CTNNB1) in multiple myeloma 
enhanced cleavage (activation) of CASP3487 while siCTNNB1 abrogated 
cisplatin-resistance in A2780 ovarian carcinoma cells, promoted apoptosis in 
vitro and suppressed tumourigenic growths in vivo.488 In a similar trend, gene 
silencing of the WNT receptor FZD7 in the current study promoted anoikis via 
the CASP3/PARP extrinsic pathway. 
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   In this study, Mcl-1 was also down-regulated in CH1 cells after shFZD7-
mediated knockdown. Of relevance, Myc, a target gene of the WNT/β-catenin 
pathway, was previously reported to directly regulate Mcl-1 expression.489,490 
Furthermore, Mcl-1 expression correlated with GSK-3β inactivity (active 
WNT/β-catenin signalling) in multiple cancer cell lines, including ovarian 
cancer cells.491 The down-regulation of Mcl-1 after FZD7 knockdown in CH1 
cells from the current study supports this observation, whereby reduced FZD7 
expression is accompanied by reduced Mcl-1 expression.  
 
   Previously, cDNA microarray screening found FZD10 expression to be up-
regulated in synovial sarcoma,492 siRNA-mediated silencing of which 
abrogated cell growth.492 FZD10 was subsequently shown to regulate 
cytoskeletal reorganization through Dvl2/3 phosphorylation to activate the 
non-canonical Rac1-JNK pathway, whereby silencing of FZD10 ablated Rac1 
activity.253 Interestingly, the endogenous expression of FZD10 in a panel of 
synovial sarcoma cell lines directly correlated with the phosphorylation status 
of Dvl2/3 proteins.253 Furthermore, the activation of Rac1 by Dvl2/3 
phosphorylation enhanced anoikis-resistant anchorage-independent 
growths.253 More recently, siFZD7-mediated knockdown in CH1, PA1 and 
OV17R cells reduced phosphorylated DVL2 (DVL2 pSer143) co-localization 
with γ-tubulin in the centrosome.243 In addition, RhoA activity was suppressed 
and Rac1 activity increased after FZD7-silencing.243 In the current study, 
Dvl2/3 proteins were shown to be dephosphorylated after shFZD7-mediated 
knockdown in OV17R cells but not in CH1 cells. Interestingly, total proteins 
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for both Dvl2 and Dvl3 were down-regulated in OV17R:778 cells. The cause 
of this is unclear, though it is noted that CH1:778 cells do show down-
regulated total Dvl3 proteins as well, suggesting that the CDS region targeted 
by the shFZD7:778 construct may result in a non-functional truncated protein 
that plays a role mediating Dvl protein expression. Of more relevance, it 
would be of interest to determine if Dvl2/3 proteins do indeed play a role in 
mediating anoikis of ovarian cancer in the current model. 
 
   Cyclin D2 (CCND2) is one of the three human members of D–type cyclins 
responsible for initiating the G1→S transition during cell cycle progression by 
activating various cyclin dependent kinases (Cdk), including Cdk4/6.493 
CCND2 expression may be regulated by the WNT target gene c-Myc,392,494,495 
NF-κB496-499 or PITX2,431,500  which is an effector and regulator of WNT/β-
Catenin signalling (refer to section 1.3 of ‘Introduction’). CCND2 has been 
reported to be overexpressed in chronic lymphocytic leukemia499 and 
significantly down-regulated in adherent cultures of prostate cancer stem 
cells.501 In ovarian cancer, aberrant methylation of CCND2 promoter leads to 
down-regulated CCND2 expression and also poorer disease-free survival.502  
In murine ovarian granulosa cells, follicle-stimulating hormone (Fsh) up-
regulates Ccnd2 expression to drive cell growth, ablation of Ccnd2 in mice 
resulted in hypoplasia.503 In the current study, the mechanism by which how 
CCND2 is up-regulated after shFZD7-mediated knockdown in OV17R cells is 
unclear. As CCND2 can be regulated by c-MYC, a WNT target gene, it was 
expected that the knockdown of FZD7 would reduce WNT activity and thus 
reduce expression of WNT target genes. Also, cyclin dependent kinase 
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inhibitor 1B (CDNKN1B/ p27Kip1) inhibits cyclin D-Cdk4 complex formation 
(reviewed in Chu, Hengst and Slingerland, 2008).504 Interestingly, c-MYC has 
been known to negatively regulate p27Kip1 expression, as such, there may be a 
correlation between CCND2 and p27Kip1 expression in OV17R shFZD7 cells. 
More needs to be done to verify if c-MYC is indeed down-regulated in the 
FZD7 knockdown model to prove this. The involvement of PITX2 in 
regulating CCND2 seems unlikely in OV17R cells as that pathway requires 
DVL2 activity, which is clearly de-phosphorylated after shFZD7 knockdown 
in OV17R cells. Interestingly, activation of WNT/β-Catenin signalling by use 
of a GSK-3β inhibitor mediated cisplatin resistance by blocking nuclear 
translocation of NF-κB.505 It is tempting to speculate that the knockdown of 
FZD7 disrupts WNT/β-Catenin activity, thus allowing NF-κB nuclear 
translocation to drive CCND2 expression. As such, aside from c-MYC, it 
would be of interest to see if NF-κB is involved in regulating CCND2 after 
shFZD7-mediated knockdown as well.  
 
   WLS acts as a cargo transporter molecule for WNT ligands, carrying them 
from the rough ER to the cell surface for receptor binding. As such, targeting 
of WLS seemed an attractive alternate strategy to verify the role of WNT 
during spheroid formation. Interestingly, WLS up-regulated protein expression 
was observed in spheroids formed by various ovarian teratocarcinoma and 
adenocarcinoma cell lines, indicating active WNT transportation in spheroids, 
presumably for secretion and activation of the pathway/s involved. 
Knockdown of WLS slowed down the rate of spheroid formation in CH1 cells 
but did not fully abrogate spheroid formation. Interestingly, the eventual size 
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of spheroids in CH1:shWLS cells matched that of the empty vector control 
cells, at an approximate one-week lag period. Furthermore, WLS-mediated 
knockdown did not show significant increment in anoikis activity in PA1 and 
OV17R cells, which supports the relative slower growth rates of CH1 shWLS 
cells: inhibition of WLS slows suspension culture growth but not induce 
anoikis as opposed to what was observed in FZD7 knockdown model. It may 
be that decreased WLS activity dampened certain elements of cell cycle. Of 
some relevance, conditional deletion of Wls in mice models impaired hair 
follicular development, resulting in hair cycle arrest in the telogen or early 
anagen phase, accompanied by reduced proliferation.506 Similarly, Wls loss of 
function (LOF) mice models show impaired hair growth and stunted body size 
in another study.507 Interestingly, cyclin D1 (Ccnd1, a WNT/β-catenin target 
gene) was enriched in the telogen bulge of hair follicles but not in highly 
proliferative Ki-67Hi anagen cells, suggesting that a pool of hair follicular stem 
cells in telogen phase with high Ccnd1 expression differentiates into transit 
amplifying cells to mediate anagen phase growths.508 Taken together, it may 
be that the suppression of Wls in these cells suppressed Ccnd1 expression, 
thus arresting these cells in the telogen phase. In a similar way, inhibition of 
WLS in ovarian cancer may have the same effect during spheroid formation, 
whereby stem-like/ progenitor cells are unable to proliferate as normally 
would due to inhibition of WNT activity, thus a slower rate of growth was 
observed. The finding of elevated WLS expression in spheroids formed would 
seem to support this hypothesis, whereby increased WLS activity may indicate 
a highly proliferative environment, inhibition of which disrupts proliferative 
stimulants (such as CCND1) from being transcribed to drive proliferation. 
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Conclusion and Future Directions 
   In conclusion, the data from the current study shows FZD7 to play a role in 
protecting ovarian teratocarcinoma and adenocarcinoma cells from undergoing 
anoikis. Moreover, the cells with reduced FZD7 expression undergo 
cytoskeletal reorganization, as evident by the distribution of F-actin, 
presumably through the mediation of Dvl2/3 adaptor protein. 
 
   While the findings of this study may be preliminary, it would be of interest 
to validate the role that Mcl-1 plays in CH1 shFZD7 cells. One way of testing 
this would be to either overexpress Mcl-1 in CH1 shFZD7 cells to test if Mcl-
1 overexpression will rescue CH1 shFZD7 cells from anoikis. Conversely, 
Mcl-1 may also be targeted for gene silencing in CH1 shFZD7 cells 
(generating double knockdowns) to determine if abrogation of Mcl-1 
expression will further enhance anoikis. Other genes that may be targeted 
include CASP3 and PARP. The abolishment of anoikis by targeting these 
genes after shFZD7-mediated knockdown will clearly show the dependence of 
the executor caspase (CASP3) in mediating anoikis. While the results of this 
study is of interest, one must acknowledge that this study did not include a 
FZD7 rescue model, which would undoubtedly make the role of FZD7 in 
inducing anoikis more convincing. As such, it is proposed to generate 
constructs that will enable stable FZD7 expression to facilitate the rescue 
study. Similarly, it will be of great interest to determine if the re-introduction 
of FZD7 would restore DVL2/3 phosphorylation. Conversely, the phenotypes 
of the double knockdowns of either FZD7/DVL2 or FZD7/DVL3 will help 
further determine if these proteins do indeed contribute towards anoikis. 
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   Also, it will be of interest to see if β-catenin is cleaved by CASP3 after 
FZD7 knockdown, which can be easily carried out with probing immunoblots 
of whole cell lysates against a β-catenin antibody. In addition, it was not 
clearly shown whether β-catenin was involved in mediating the shFZD7 
phenotype. The role of β-catenin could be tested by treating spheroid-forming 
cells with β-catenin-specific inhibitors, such as inhibitors of β-catenin 
responsive transcription (iCRTs).509 
 
   It has been previously reported that transient FZD7 knockdown disrupted 
cell cycle progression, evident by increased G0/G1 subpopulations.243 As such, 
cell proliferation after shFZD7-mediated knockdown could be better 
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